Dynamics of p53 tetramers in live single cells by Gaglia, Giorgio
 
Dynamics of p53 tetramers in live single cells
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation No citation.
Accessed February 19, 2015 4:14:19 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12269874
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAADynamics of p53 tetramers in live single
cells
A dissertation presented
by
Giorgio Gaglia
to
The Committee on Higher Degrees in Systems Biology
in partial fulﬁllment
of the requirements
for the degree of
Doctor of Philosophy
in the subject of
Systems Biology
Harvard University
Cambridge, Massachusetts
February 2014©2014 Giorgio Gaglia
All rights reserved.Advisor: Professor Galit Lahav Giorgio Gaglia
DYNAMICS OF P53 TETRAMERS IN LIVE SINGLE CELLS
Abstract
Protein homo-oligomerization is the process through which identical peptides bind
together to form higher order complexes. Self-interactions in many cases are con-
stitutive and stable, used as building blocks for biological structures, such as rings,
ﬁlaments and membranes. Further, homo-oligomerization can also be a regulatory
process that inﬂuences the proteins’ function such as change in transcriptional ac-
tivities for transcription factors. Innovative methods to measure oligomerization
in live cells are needed in order to understand regulation and function of homo-
oligomerization in the native cellular context. This thesis examines the case of the
tumor suppressor p53, whose homo-tetramerization greatly inﬂuences its activity
as a transcription factor. We develop methods to quantify p53’s self-interaction in
individual living cells and follow it in time after DNA damage. The two meth-
ods we developed have complementary qualities and different applications. We
ﬁrst use ﬂuorescent correlation spectroscopy to study the molecular events occur-
ring in the ﬁrst three hours of the p53 in response to double strand breaks. We
ﬁnd that in the absence of stress p53 is present in a mixture of, monomers, dimers
and tetramers. When damage is sensed, oligomerization is rapidly induced and
nearly all p53 is found bound in tetramers. We combine our data with a math-
ematical framework to propose the existence of a dedicated mechanism trigger-
ing p53 oligomerization independently of protein stabilization. Next, we use bi-
molecular ﬂuorescent complementation to probe for tetramerization in the longer
iiitimescales of p53’s response to ultraviolet radiation. In this context we ﬁnd that
even though the rate of p53 accumulation increases with the dose of radiation, p53
tetramers are formed at a steady rate. We hence propose the existence of an in-
hibitory mechanism that prevents the oligomerization reaction from following a
linear input-output relation. We identify ARC, a known cofactor of p53, as part
of this inhibitory mechanism. Downregulation of ARC restore the linear relation
between to total and tetrameric p53. Finally, in both experimental setups higher
oligomerization lead to an increase in p53 activity, underscoring the connection
between regulation of oligomerization and the transcriptional activity of p53 in
cancer cells. Collectively, this work emphasizes the importance of precise mea-
surements to investigate the regulation and function of higher order complexes
and provides generally applicable methods to quantify homo-oligomerization in
live single cells.
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Introduction
1.1 THE TUMOR SUPPRESSOR P53
The transcription factor p53 is a crucial tumor suppressor in humans and animals.
Mutations in the gene expressing p53, TP53, are found in more than 50% of hu-
man tumors of various types including cancer of the lungs, colon and leukaemia
[1]. Cancer is a set of diseases in which cells abnormally proliferate, survive and
invade, leading to tissue malfunction and failure. Whilst the term cancer is used
to encompass a broad set of diseases, all of them arise because of accumulation of
genomic (and in some instances epigenetic) alterations ranging from single point
mutations, chromosome re-arrangements and to genomic loss. The tumor suppres-
sor p53 is a stress-response regulator at the center of a complex protein network
that is able to drive a variety of cellular responses such as DNA repair, cell-cycle
arrest, apoptosis and senescence. These mechanisms are active in cells to avoid the
propagation of genetic mistakes either by allowing time to repair the DNA before
1cell division or, if the damage cannot be ﬁxed, by triggering terminal cell fates. Be-
cause of the centrality of p53’s function in protecting the genetic material, it has
been referred to as the “guardian of the genome”.
The p53 network consists of a number of proteins involved in sensing cellular
stresses, relaying the signal to p53 and enabling p53’s activity as a transcription
factor. Stresses such as DNA damage, hypoxia and ribosomal stress activate signal
mediators that modify and stabilize the p53 protein (Figure ??). These signaling
events activate p53 by altering its half-life, cellular localization, protein conforma-
tion and its ability to bind DNA. While there are possible means of regulation of
p53 mRNA [2] it does not seem likely that they play a role in p53 dynamics af-
ter DNA damage, as the level of p53 mRNA in cells does not change after UV or
IR in the timescales of a few days [3, 4]. Activated p53 accumulates in the nu-
cleus where it recruits co-factors, binds to speciﬁc DNA sequences called the p53
responsive element (p53 RE) and triggers the transcription activation or repression
of target genes. Even though p53 also has important transcription-independent
roles [5, 6, 7], the protein works primarily as a tetrameric transcription factor. Over
120 p53-responsive genes have been identiﬁed in the human genome though not all
of them are regulated in the same conditions [8]. In fact different stresses activate
distinct transcriptional programs that include only a subset of these targets.
The core regulation of p53 abundance and activation occurs at the protein level
through post-translational modiﬁcations. More than 30 residues of p53 are either
phosphorylated, ubiquitylated, acetylated, or subject to other types of modiﬁca-
tions [1, 9]. The most fundamental mechanism for controlling p53 protein levels
occurs through ubiquitylation by Mdm2 (mouse double minute 2) that targets p53
for proteosomal degradation [10]. Even though other two E3 ubiquitin ligases,
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3Figure 1.1: Activation of the p53 pathway after cellular stress. Step 1: Cells are
subject to stress. Step 2: Signal mediator proteins trigger p53 activation induct-
ing its phosphorylation and disrupting ubiquitynation by MDM2 (mouse double
minute-2). Step 3: p53 is activated by phosphorylation; its half-life increases from
minutes to hours leading to p53 protein accumulation. Step 4: p53 is further sta-
bilized by acetyltransferases (CBP, p300, PCAF) and methyltransferases (SET9)
which also increase site-speciﬁc DNA binding. Step 5: p53 tetramers bind to p53
response elements (RE) in the DNA. Step 6: p53 regulates the expression of target
genes, both mediating transactivation and repression of target genes. Step 7: The
products of the genes regulated by p53 are involved in various pathways. Step
8: Transcriptional programs fundamental for tumor suppression are triggered
by p53 include DNA repair, cell-cycle arrest, senescence and apoptosis. ATM,
ataxia telangiectasia mutated; BAX, BCL2-associated X protein; BBC3, BCL2-
binding component-3; CDKN1A, cyclin-dependent kinase inhibitor-1A; CHK2,
checkpoint kinase-2; DDB2, damage-speciﬁc DNA-binding protein-2; GADD45a,
growth arrest and DNA-damage inducible a; p14ARF; SFN, stratiﬁn; (Figure
adapted from [8])..
Pirh2 and Cop1, seem to have redundant function to Mdm2, the latter is the main
regulator of p53, as shown by compelling biochemical evidence [11] and by the ob-
servationthatMdm2-/- micearenotviablebutcanberescuedbydoublep53knock-
out [12]. Prior to degradation, mono-ubiquitylation by Mdm2 is also responsible
for nuclear export of p53 [13]. Phosphorylation is the most frequent modiﬁcation;
after stress a vast array of kinases phosphorylates p53 at as many as 17 residues.
In general both phosphorylation and acetylation are thought to stabilize the p53
protein and increase its afﬁnity to speciﬁc promoters. However, even though the
global impact of post-translational modiﬁcations in p53 function is clear, speciﬁc
modiﬁcations were suggested to play a different role in p53 function and the effect
of individual modiﬁcations is unclear for most of them. Additionally most modi-
ﬁcations are reversible and they can transiently be added and removed after stress
or during speciﬁc cell-cycle phases [14]. Each modiﬁcation is hence kept in a ﬁnely
tuned on-off balance resulting in a “complex barcode” of modiﬁcations state that
4shifts dynamically and enables p53 to continuously integrate signals [1].
The dynamic control of p53 activity is also achieved by a series of transcriptional
feedbacks [15]. While most of the transcriptional targets of p53 accomplish key
cellular functions and stress responses, some are involved in p53 regulation. The
negative regulators of p53, the ubiquitin ligases Mdm2, Pirh2 and Cop1 are all tran-
scriptional targets of p53 and their expression in enhanced upon stress [16, 17, 18].
Important p53-responsive gene such as PTEN, p19/p14 ARF and cyclinG regulate
p53 by feedbacks acting on Mdm2. Finally other targets modify the activity of
signal mediators upstream of p53, for example,the phosphatase Wip1 that targets
ATM (see DNA damage section below).
As mentioned above, p53 works primarily as a tetrameric transcription factor.
In this work I focused on the formation of p53 homo-tetramers in response to two
DNA damaging agents, ultraviolet and ionizing radiation. In the next sections I
will introduce the p53 response to DNA damage and what is known about p53
homo-tetramerization.
1.2 THE P53 RESPONSE TO DNA DAMAGE
DNA damage is an alteration to the chemical structure of the DNA, either of the
backbone or of the bases. Chemical modiﬁcations include the break in the DNA
strands, intra- and inter-strand crosslinking and loss of base-pairing information,
all of which lead to stalled replication forks or incorrect DNA replication. Dam-
age to the DNA occurs naturally in cells and it is continuously ﬁxed by one of
the DNA repair mechanisms. However, if not properly dealt with, errors in the
ﬁdelity of DNA replication deteriorate the genetic information. The propagation
and accumulation of loss of information eventually leads to cell malfunction and
cancer. Hence timely detection of DNA damage and its efﬁcient repair represents
5a fundamental cellular activity.
Sources of DNA damage are both endogenous and exogenous to cells. Nor-
mal cellular metabolism releases reactive oxygen species, reacting nitrogen species
and alkylating agents that chemically modify DNA. Damaging chemical agents
are also absorbed from the environment, usually referred to as carcinogens. Ex-
ternal sources of damage also include ultraviolet radiation and ionizing radiation
that both cause the release of reactive oxygen species on top of having direct DNA
damaging effects.
Ultravioletradiation(UV)inducestheformationofpyrimidinedimers[19]; these
are detected and excised by the nucleotide excision repair mechanism (NER). If this
procedure fails, replication is taken over by the translesion DNA synthesis machin-
ery that replicates the DNA bypassing the lesion, a failsafe and error-prone mecha-
nism. In absence of efﬁcient repair UV lesions are devastating. Germline mutations
in the component of the NER are associated with xeroderma pigmentosum (XP), an
autosomal recessive genetic disorder that leads to hypersensitivity to UV [20]. Ho-
mozygous XP individuals develop carcinomas at a young age and rarely live past
20 years of age [21]. In response to UV radiation, p53 is activated and was shown
to predominantly trigger apoptosis [22, 23, 24].
Ionizing radiation (IR) directly ionizes and breaks DNA strands. When two
single-stranded breaks occur with 10 base pairs of each other they form double-
strand breaks (DSB), the most dangerous form of DNA break. Similar double
strand breaks can be induced chemically using radiomimetic drugs. In this study
I used neocarzinostatin (NCS), a drug permeable to cells in culture that cleaves
the DNA backbone with free radical attack causing damage closely mimicking ion-
izing radiations [25, 26]. In response to IR and radiomimetic drugs, p53 triggers
a transcriptional program that causes cells to arrest the cell cycle and to undergo
6senescence.
Ultraviolet and ionizing radiation activate the p53 network through different
pathways (Figure 1.2). Single-stranded DNA exposed by stalled replication forks
after UV activates the ataxia telangiectasia and Rad3-related protein (ATR) and its
co-factor and activator ATRIP. ATR phosphorylates p53 directly on Ser15 and Ser37
[27], and activates two other kinases, checkpoint kinase 1 (Chk1) and p38, that in
turn phosphorylate p53 on serine residues 15, 20, 33, 46 and 392 [9, 24, 28]. Instead
DSBs lead to the activation of the kinases ataxia telangiectasia mutated (ATM) and
checkpoint kinase 2 (Chk2) [29, 30], which phosphorylate p53 at multiple residues
including serine 6, 9, 15, 20 and 366 [9, 31].
In the absence of stress, many tissues have low levels of p53 protein. Mdm2 con-
tinuously ubiquitylates p53 and targets it for degradation, resulting in a half-life
of 6-20 minutes [8]. Post-damage phosphorylations on p53 disrupt the binding to
Mdm2 and p53 protein accumulates. Since Mdm2 is itself a target of p53 transcrip-
tional activity, the level of Mdm2 eventually increases until it is enough to over-
come the stabilization of p53; this negative feedback leads to downregulation of
p53 and to pulsatile dynamics [32]. In the past ten years the Lahav laboratory and
other groups have characterized the pulsatile dynamics of p53 protein in culture
cells after DNA damage using ﬂuorescence microscopy of GFP-tagged p53. This
is possible since the dynamics of p53 protein are mostly modulated at the protein
level.
1.3 DYNAMICS OF P53 IN SINGLE LIVING CELLS
The dynamics of p53 were shown to depend on the speciﬁc DNA damage. Af-
ter UV radiation p53 undergoes a single pulse of accumulation whose magnitude
and duration is dependent on the radiation dose [33]. While at population level
7the dynamics of p53 protein after IR appear to display multiple damped pulses
[34], single cells studies show that p53 undergoes a series of pulses with conserved
height and width [35, 36]. However the cells slowly lose synchrony of pulsing and
stop pulsing at different times, effects that are masked at cell-population level.
Recent work for the Lahav laboratory has shown that the difference in p53 dy-
namics after UV versus IR is due to a second negative feedback driven by another
p53 transcriptional target, Wip1 [35]. Wip1 is a phosphatase that dephosphorylates
p53, decreasing its stability. In response to IR, Wip1 is also able to target ATM,
inhibiting its activity and disrupting the signaling upstream of p53. Since ATR’s
activity does not depend on phosphorylation, ATR is unaffected by Wip1 and this
negative feedback does not occur after UV (Figure 1.2 adapted from [33]).
The total level of p53 in cells is an important indicator of its activity but it does
not capture its functional state [37]. Post-translational modiﬁcations are a prime
example of how the state of p53 majorly changes its activity level and the subse-
quent cellular outcome. Another aspect of p53 that changes its activity is its homo-
oligomerization state. In fact, p53 forms homo-tetramers in vitro and in vivo and
these represent the functional unit of p53 activity. In the next sections I outline
what is known about p53 tetramerization, the open questions in the ﬁeld and the
challenges to study it in live cells.
1.4 HOMO-OLIGOMERIZATION OF P53
Protein homo-oligomerization is the formation of speciﬁc protein aggregates of
multiple identical subunits. Homo-oligomerization is extremely common in na-
ture: recent studies have shown that around 60% of proteins in the Protein Data
Bankandmorethan2/3ofhumanenzymesformshomo-oligomers[38,39]. Oligomer-
ization can serve structural purposes, for example in viral capsids where the self-
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Figure 1.2: Effects of DNA damage through the p53 pathway. Different sources
of DNA damage, such as ionizing radiation (IR) and ultraviolet radiation (UV),
activate the p53 pathway through distinct signals, double strand breaks and ex-
posure of single stranded DNA respectively. These signals engage overlapping
yet separate networks of proteins regulating p53, leading to different dynamics
of p53 protein levels after stress. These dynamics trigger distinct cellular fates
(adapted from [22, 33]).
9assembly of a single (or a few) proteins allows formation of a 3-dimensional struc-
ture. These complexes are extremely stable with oligomeric dissociation constant
in the nanomolar range [40]. In many other instances oligomerization is a regulated
step that changes the function of the protein, as for the case of G-protein coupled
receptors [41], C/EBP family transcription factors [42] and the apoptotic protein
Bax [43].
The p53 protein forms homo-oligomers through a C-terminal small protein do-
main called the tetramerization domain (TD) spanning amino acids 326-355 (Figure
1.3A). The structure of the TD consists of a beta-sheet and an alpha-helix sepa-
rate by a sharp turn (Figure 1.3B). The domain forms homo-dimers by anti-parallel
interactions between the beta-sheets and by anti-parallel helix packing (red and
yellow chains in Figure 1.3B). Once primary dimers are assembled the tetrameriza-
tion interface forms by the alpha-helices, four of which come together in a 4-helix
tetrameric bundle [44, 45]. Since dimerization is required before tetramerization,
tetramers are considered “dimers of dimers” and p53 does not exist in trimeric
form. While other parts of the protein are known to create homo-oligomeric con-
tact points, the tetramerization domain is central to the formation of oligomers as
in its absence oligomers are not observed [46, 47].
Puriﬁcation of full-length wild-type p53 has proven extremely challenging and
a complete protein structure of wild-type is not available. In vitro and structural
studies either use fragments of the p53 protein to isolate speciﬁc domains [45, 48]
or use super stable mutants developed in the Fersht laboratory in Cambridge UK
[49, 50, 51, 52]. Tetramerization of p53 has been studied with many in vitro methods
that yielded to a comprehensive understanding of the reaction.
Dimers of p53 form at extremely low concentrations; their dissociation constant
has only recently been measured to be Kd = 0.55 ± 20 nM [53]. Protein folding stud-
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Figure 1.3: Scheme of the p53 protein domains and structure of the tetrameriza-
tion domain. A. The p53 protein spans 393 amino acids usually divided into
three functional domains. The N-terminal domain is made up of the transactiva-
tion domain and a Src homology 3-like (SH3) domain. The central core consists
only of the DNA-binding domain through which it contacts the DNA directly.
The tetramerization domain resides in the C-terminal end together with a nu-
clearlocalizationandexportsignals(respectivelyNLSandNES)andaregulatory
domain (panel adapted from [9]) B. Ribbon model of the structure of tetramer-
ization domain of p53. Two different orientations are shown and each subunit
of the domain is colored differently. On the right side panel the side chains of
key residues used for disrupting the tetramerization reaction (L344 and L348)
are highlighted. Panel adapted from [44].
11ies have shown that the dimerization reaction occurs while the peptide folds, with
the protein passing from an unfolded monomeric state straight to a folded dimeric
state [54]. Interestingly, an in vitro translation study by Nicholls et al. showed that
when two mRNA constructs producing distinct p53 proteins are translated at the
same time, only homo-dimers are detected [55]. This hence implies that dimer-
ization occurs co-translationally, in proximity of the polysome, while the protein is
being translated. Once dimerization occurs the two alpha-helices of the TD form an
hydrophic patch responsible for tetramerization [44]. Tetramerization is markedly
less stable than dimerization with a Kd ~ 200nM – 2mM [53, 56, 57, 58]. Based on
measurement of p53 protein concentration of 140nM (measured in MCF7 cell by
ELISA [59]) it was suggested that, in absence of stress p53, is mainly dimeric in
cells.
1.5 REGULATION OF TETRAMERIZATION
p53 binds DNA as a tetramer [60]. DNA sequences containing the p53 respon-
sive element offer a surface for cooperativity facilitating tetramerization [56]. Cer-
tain post-translational modiﬁcations have been shown to enhance tetramerization,
namely Ser392 phosphorylation [58] and Tyr327 nitration [61], while others, like
acetylation of C-terminal lysines, inhibit oligomerization [62]. Modiﬁcations of p53
can also affect indirectly the level of tetramerization by recruiting co-factors of p53:
for example phosphorylation of Ser366 or Thr387 was shown to recruit members
of the 14-3-3 protein family that increase p53 tetramerization [57, 63].
Co-factor binding also plays a crucial role in the regulation of p53 oligomeriza-
tion. The binding of certain co-factors induces tetramerization, like the aforemen-
tioned 14-3-3sv, the redox factor-1, Ref-1 [64] and p300 [65]. Other proteins instead
interact directly with the tetramerization domain of p53 and inhibit competitively
12tetramerization or even dimerization. This category includes the members of the
S100 family [66] and the apoptotic repressor with CARD domain (ARC) [67].
1.6 FUNCTION OF P53 TETRAMERIZATION
The most important feature of p53 tetramerization is that it is essential for efﬁcient
DNA binding and hence for its transcriptional activity. Kawaguchi and cowork-
ers extensively tested the transcriptional capacity of a library of mutants in the
tetramerization domain with a reporter system in yeast [68]. Their study showed
that mutations that rendered p53 monomeric lead to a complete loss of transcrip-
tional activity while some mutants that formed dimers but not tetramers retained
a low capacity of activating target genes. Furthermore, in vitro testing showed that
dimers of p53 can still bind DNA but with two orders of magnitude lower binding
afﬁnity [60].
Two germline mutations in the tetramerization domain that cause complete loss
of oligomerization, R337C and L344P, have been strongly linked to Li-Fraumeni
syndrome, a disease characterized by early onset of cancer [69]. Elevated incidence
of another germline p53 tetramerization mutation, R337H, has been observed in
children affected by adrenocortical carcinoma (ACC) in southern Brasil [70]. While
cancer mutations commonly target DNA binding domain of p53, somatic muta-
tions in the TD have not been frequently observed in cancers. A higher incidence
of mutations in the TD would be expected, since in cells the loss-of-function phe-
notype of TD mutants is similar to that of mutants in the DNA binding domain.
However a plausible hypothesis is that the loss of oligomerization ability caused
by mutation in one allele of p53 is unable to affect the function of the wild-type
p53, while DNA binding mutants that retain the capacity to oligomerize can exert
a dominant-negative effect [71, 72].
13For this study, amongst the mutations that affect tetramerization I selected two
point mutations in residue Leu344 as a control (Figure 1.3B). Alanine substitution
at this residue (L344A) renders the p53 protein unable to form tetramers while
retaining the capacity of efﬁciently form dimers [54, 73]. Since leucine 344 is part
of the alpha helix in the TD, mutation to proline disrupts the structure of the helix
and of the entire TD, making p53 L344P strictly monomeric [74].
BesidesDNAbinding, p53tetramerizationisalsoimportantforpost-translational
modiﬁcations and cellular localization. Speciﬁcally phosphorylation of several ser-
ines (residues 6, 9, 46 and 315) and acetylation of C-terminal lysine 382 is abrogated
in oligomerization defective mutants [75, 76]. Moreover, tetramerization is thought
to mask the nuclear export sequence (NES, Figure 1.3A) preventing access to the
export machinery and causing p53 to accumulate in the nucleus [77].
While the tetramerization reaction has been extensively and successfully stud-
ied in vitro in the test tube, our understanding of the regulation and function of
p53 oligomers in live cells is extremely limited. First of all we still do not know the
stoichiometry of p53 in cells. Given that tetramerization is altered by multiple post-
translational modiﬁcations and co-factors, some of which facilitate oligomerization
while other disrupt it, the in vitro measurements of dissociation constants can only
be indicative. Further, the role of tetramerization has been explored by either mu-
tating p53 or by silencing and overexpressing possible regulators. However it is
still unclear what happens to the oligomerization state of p53 after a stimulus, such
as DNA damage. This question is further complicated by the fact that the total p53
protein itself undergoes complex dynamics after DNA damage that would affect
the stoichiometric balance even in absence of speciﬁc regulation of the oligomer-
ization reaction.
141.7 MEASURING TETRAMERIZATION TO QUANTIFY THE ACTIVE FORM
OF P53
One reason for why the above questions have remained unanswered is that mea-
suring protein self-interactions in cells is challenging. The common methods to
identify protein interaction rely on the putative binding partners differing in size
or charge. On top of this, most techniques are able to detect homo-dimers but not
any higher-order oligomer. The aim of my work was to quantify p53 tetrameriza-
tion accurately in live cells. Hence this required the development of experimental
techniques that are discussed in the following paragraphs.
In general, protein quantiﬁcation in live cells relies on ﬂuorescent protein tag-
ging. Tagged p53 has previously been shown to accurately report for endogenous
p53 and it has been used to study its dynamics in single cells [32, 35, 36]. In order
to extend ﬂuorescent reporters to probe for protein oligomerization a technique
that allows resolution of the protein aggregates composition is required. To this
extent I used ﬂuorescence correlation spectroscopy (FCS) to measure the aggrega-
tion state of CFP-tagged p53 in single live cells. Another possible method to mea-
sure oligomerization is to use two p53 constructs differentially tagged and probe
for their interaction, for example using complementary fragments of ﬂuorescent
proteins that only become ﬂuorescent upon binding. This is called bimolecular ﬂu-
orescence complementation (BiFC) and it is the second method I used to measure
p53 oligomerization.
1.7.1 Fluorescence Correlation Spectroscopy (FCS)
FCSisoneofthetechniquesusedtoanalyzetheﬂuctuationsinﬂuorescentintensity
of a small sample volume; there are other ways of analyzing such data like photon
15counting histogram and molecular brightness analysis, and collectively this group
of methods is called ﬂuorescent ﬂuctuation spectroscopy (FFS) [78, 79, 80]. These
methodsrelyonprobingasolutionofﬂuorophoresandmeasuringtheﬂuorescence
intensity of a small subvolume in time with micro- to millisecond resolution. The
variations of the intensity measurement, referred to as ﬂuctuations, come from the
movement of ﬂuorescent molecules to and from the volume. As the diffusion of
single ﬂuorophores produces ﬂuctuations of smaller amplitude than multiple ﬂuo-
rophores bound together, the aggregation state of these molecules can be calculated
from the analysis of the ﬂuctuations.
In order to maximize the chances of successful a FCS experiment, the measure-
ment requires the greatest accuracy possible and hence a speciﬁc experimental
setup is needed (Figure 1.4). Firstly a small observation volume of ~ 1 fL is re-
quired. This can be obtained by confocal microscopy or two-photon excitation, but
the latter is usually preferred as it lowers photobleaching. Instead of to a CCD
camera the light collected from the sample is then directed through a photode-
tector, like a photomultiplier tube (PMT) or avalanche photodiode (APD). These
devices have high gain and low dark counts, in order to avoid missing any photon
hitting the sensors, and fast response time to be able to respond to high frequency
of photon excitation [81]. Finally the data is stored in a photon counting acquisition
card that keeps the complete history of photon counts events on which the analysis
is performed.
Different types of analysis can be performed on the photon counts data, depend-
ing on the information to be extracted. FCS consists in binning the data in time and
calculating the autocorrelation of the resulting time trace. The details of the setup
and analysis I use can be found in the Materials and Methods section of Chapter 2
of this study. FCS and related ﬂuctuation techniques have been used in cells and
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Figure 1.4: Schematic of two-photon FFS instrument. A laser provides two-
photon excitation light source. The excitation light is sent to the inverted mi-
croscope. Either a PMT or APD detects the ﬂuorescence generated by the two-
photon excitation. The data is the subect of analysis by ﬂuorescent correlation
spectroscopy or similar techniques (adapted from [81]).
17model systems to study protein aggregation [82], complexes of viral proteins like
Gag and Vpr [83, 84], formation of membrane lipid layers [85] and receptor homo-
meric aggregates [86]. These studies, however, use the diffusion coefﬁcient to draw
conclusions regarding interaction and oligomerization. In this work I used FCS to
calculate the so-called “particle brightness”, a parameter that reports for the stoi-
chiometry of ﬂuorophore aggregates travelling through the volume: this analysis
was pioneered by the group of Enrico Gratton (Department of Physics, University
of Illinois, Urbana Champaign) who also showed that the method is appropriate
to measure oligomerization in human cells [79, 87]. In Chapter 2, I employed the
particle brightness to study the activation of p53 tetramerization after DNA double
strand breaks.
While FCS is a powerful and precise technique, its application to live specimens
has some limitations. The experimental setup is not optimal for human cells allow-
ing only 3-5 hours long measurements before stress-response pathways become
active. Since the dynamics of p53 after DNA damage are in the timescale of hours
[36], only the initial events of p53 activation can be observed by FCS. Moreover,
the length of the measurements (~5 minutes per cell per timepoint) does not al-
low collecting more than 5-8 cells per experiment. For these reasons I developed
a second method to quantify p53 oligomerization in single cells that makes use of
epiﬂuorescent microscopy.
1.7.2 Bimolecular Fluorescence Complementation (BiFC)
Protein-fragment complementation is a technique for which a reporter protein is
split in two fragments that can bind to each other and reconstitute the original
protein. The fragments of the protein are not active alone but when the full protein
is reconstituted its activity is restored. Common examples of proteins used for this
18purpose are enzymes like dihydrofolate reductase and beta-lactamase [88, 89] and
the split version of the transcription factor Gal4, the base of the yeast two-hybrid
system to test protein-protein interactions.
The ﬂuorescent version of protein complementation is called bimolecular ﬂuo-
rescent complementation (BiFC) and it involves splitting a ﬂuorescent protein and
disrupting the ﬂuorescent beta-barrel core [90]. The resulting two fragments are
not ﬂuorescent in isolation and have low afﬁnity for each other. Hence they do
not bind each other unless they are tagged to interacting proteins. When the latter
binds the non-ﬂuorescent fragments are kept in close proximity allowing for the
protein to reconstitute and for the ﬂuorescent core to mature [91].
In order to use BiFC to measure oligomerization dynamics, speciﬁc controls are
required. First, even though the ﬂuorescent fragments afﬁnity is low, there still
could be unspeciﬁc binding and hence background ﬂuorescence. Moreover, com-
pared to similar methods like FRET, a major drawback of BiFC is that the reconsti-
tution reaction is irreversible as the fragments are not able to separate again. Hence
it is important to test whether the tagging of split fragments to the protein of inter-
est does not modify its dynamics. Lastly BiFC theoretically reports only for dimer-
ization of the protein of interest not for higher order oligomers, like tetramers.
In the case of p53 I overcame these challenges as follows: the oligomerization
mutants described above (p53 L344A and p53 L344P) served as controls to calcu-
late the background ﬂuorescence coming not only from unspeciﬁc binding but also
from sources other than the tetramerization domain of p53. Secondly, the dynamics
of p53 after DNA damage are extremely well characterized and hence it is possi-
ble to test directly the effect of the split ﬂuorescent tagging on the p53 behavior
after stimulus [33]. Finally, p53 dimers were shown form co-translationally in vitro
[55]. This implies that both monomers in each dimer of p53 are translated from
19the same mRNA and carry the same fragment of the ﬂuorescent protein. Since the
fragments are not symmetric [90] the dimers would not be able to form a ﬂuores-
cent protein until two dimers carrying complementary fragments come together as
a tetramer. In this scenario the BiFC setup reports directly for tetramers. In Chapter
3, I employed a BiFC setup to test the co-translationality of p53 dimers in cells and
to measure the dynamics of total p53 protein and p53 tetramers in live single cells
after UV radiation.
20Chapter 2 : Activation and
Control of p53 tetramerization
Homo-oligomerization is found in many biological systems and has been ex-
tensively studied in-vitro. However, our ability to quantify and understand
oligomerization processes in cells is still limited. We used ﬂuorescence corre-
lation spectroscopy (FCS) and mathematical modeling to measure the dynam-
ics of the tetramers formed by the tumor suppressor protein p53 in single liv-
ing cells. Previous in vitro studies suggested that in basal conditions all p53
molecules are bound in dimers. We found that in resting cells p53 is present in
a mix of oligomeric states with a large cell-to-cell variation. After DNA damage,
p53 molecules in all cells rapidly assemble into tetramers before p53 protein
levels increase. We developed a model to understand the connection between
p53 accumulation and tetramerization. We found that the rapid increase in p53
tetramers requires a combination of active tetramerization and protein stabiliza-
tion, however tetramerization alone is sufﬁcient to activate p53 transcriptional
targets. This suggests triggering tetramerization as a new mechanism for acti-
vating the p53 pathway in cancer cells. Many other transcription factors homo-
oligomerize, and our approach provides a new way for probing the dynamics
and functional consequences of oligomerization.
212.1 INTRODUCTION
Homo-oligomerization, the formation of a protein complex out of identical com-
ponents, is extremely common in nature; in E. Coli it is estimated that 35% of pro-
teins form homo-oligomers [40] with an average of 4 subunits per complex. In
yeast and human cells many transcription factors undergo homo-oligomerization,
which has been shown to be crucial for their function [92]. The molecular dynamics
of oligomerization have been studied for some proteins in vitro, but no study has
quantiﬁed discrete numbers of oligomers in a dynamic oligomerization process in
live single cells. Here we focus on the homo-tetramers formed by the tumor sup-
pressor p53 and quantify the fraction, dynamics and function of homo-oligomers
in single living cells in response to DNA damage.
p53 is a stress-response transcription factor that orchestrates cell fates decisions
such as cell-cycle arrest, senescence and apoptosis. Tetramerization of p53 is re-
quired for its direct binding to DNA [48, 93]. Mutations in the p53 tetramerization
domain (326-356 aa) lead to a reduction in, or loss of, its transcriptional activity
in cells [68] and were shown to cause early cancer onset, known as Li-Fraumeni
syndrome [70, 74].
In in vitro studies, p53 ﬁrst assembles into homo-dimers with a Kd of ~1 nM
[53]. These dimers then come together in tetramers with a Kd of ~100nM-1µM
[53, 56, 57, 58]. The Kd of tetramerization in vitro can be lowered by speciﬁc post-
translational modiﬁcations [57, 58, 94]. Based on these measurements and the es-
timated p53 concentration in cells of 140 nM [59] it has been proposed that p53
should be primarily dimeric in basal conditions and that it forms tetramers in
stressed conditions [9]. However there is currently no direct experimental evidence
for this in cells.
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Figure 2.1: Experimental setup and controls for p53 functionality A. Schematic
view of FCS measurement. The FCS measurements were obtained with a two-
photon excitation laser in the nucleus of live cells. The laser creates an obser-
vation volume of ~ 1 fL, through which ﬂuorescently labeled p53 molecules dif-
fuse. C-terminal tagging of p53 with mCerulean does not disrupt the dynamics
and function of p53. B. p53 levels were measured using immunoblots in parental
MCF7 cells, MCF7 cells silenced for p53 (p53 shRNA) and cells expressing p53
tagged to mCerulean. C. mRNA levels of p53 target genes measured using qPCR.
The reintroduced tagged p53-mCerulean is able to induce expression of p53 tar-
get genes. D. Wild-type p53 forms dimers (“D”) and tetramers (“T”). Mutant p53
L344A forms dimers but no tetramers and p53 L344P mutant is only monomeric
(“M”).
23We used ﬂuorescence correlation spectroscopy (FCS) to quantify the fraction of
p53 monomers, dimers and tetramers in living single cells in a basal state and post
DNAdamage. FCSiswidelyusedinvitrotomeasureproteinhomo-oligomerization,
including p53 tetramerization [53, 93] but has only rarely been used in living cells
forthispurpose[95]. FCSprovidesdirectmeasurementsoftheintensityandbright-
ness of ﬂuorescent molecules [96]; the intensity reports the numbers of ﬂuorescent
molecules in the volume and therefore provides a measure of total protein con-
centration. The brightness captures the average ﬂuorescent intensity of p53 aggre-
gates, hence higher brightness indicates higher oligomerization state (Figure 2.1A).
Note that the brightness captures only the interactions between ﬂuorescently la-
beled molecules and hence it is not affected by non homo-oligomeric binding in-
teractions, even when these might affect the diffusion rate (see Methods).
2.2 RESULTS
2.2.1 p53 is present in a mixture of oligomeric states in cells.
ForFCStoprovideanaccuratemeasureofp53oligomerizationstate, allp53molecules
must be ﬂuorescently labeled. We therefore established a cell line silenced for
endogenous p53 [97] to which we reintroduced an exogenous p53 tagged with
mCerulean, a monomeric version of CFP (Figure 2.1B). Fluorescently tagged p53
was previously shown to mimic the dynamics of endogenous p53 in response to
DNA damage [35] and here we show that its function as a transcription factor is
analogous to wild-type p53 (Figure 2.1C). We also constructed cell lines express-
ing two p53 mutants, which have been extensively tested in vitro: p53 L344A - a
mutant that cannot form tetramers but does form dimers and p53 L344P - a mu-
tant that cannot form dimers or tetramers and is therefore only monomeric (Figure
2.1D).
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Figure2.2:Distributionofp53oligomericstatesbeforeandafterDNAdamageA.
p53 oligomerization is induced after DNA damage. The oligomerization state is
represented by the particle brightness. B. Percentages of p53 monomers, dimers,
and tetramers in basal conditions (left) and after DNA damage (right). C. An
example for FCS autocorrelation traces and ﬁts in one cell. Autocorrelation G(t)
is calculated by averaging ﬁve 30 second measurements at a speciﬁc time point
after DNA damage. The autocorrelations were ﬁt to theoretical curves assum-
ing Brownian diffusion (red line). The values for the diffusion constant ‘D’ and
brightness ‘e’ for the correspondent traces are calculated by the ﬁtting of the au-
tocorrelation curves.
25We measured the particle brightness of wild-type p53 and the two mutants at rest
and after DNA damage induced by the radiomimetic drug NCS (Figure 2.2). The
increase in brightness following DNA damage results from tetramerization since
only the brightness of wild-type p53 increased (Figure 2.2A). We used the bright-
ness of the monomeric mutant L344P, e(mono), to calculate the relative abundance
of p53 in each oligomeric state by breaking up the intensity I and the number of
moleculesNintothespeciﬁcnumbersofp53monomersM,dimersDandtetramers
T using the following equation:
Particle Brightness = # = <I>
<N> = #(mono) 
1+2 D
M+4 T
M
1+ D
M+ T
M
The FCS brightness analysis was conﬁrmed using photon counting histogram
analysis (PCH) [78] on the ﬂuorescence ﬂuctuation data (Figure 2.3A). We con-
ﬁrmed the reliability of the FCS brightness analysis for quantifying oligomeriza-
tion by showing that the brightness of ﬂuorescent tandem dimers is double the
brightness obtained from monomers in cell lysates using both FCS and PCH anal-
ysis (Figure 2.3B and C). Notably control cells lacking ﬂuorescent reporter showed
minimal background and no FCS signal (Figure 2.3D and E) and photobleaching
was found to be minimal (<10%) in our experimental setup (Figure 2.3F).
Based on the particle brightness obtained from the p53 mutants and the wild-
type p53 (Figure 2.2A) we calculated that at rest the majority of p53 is bound in
dimers with 29% unbound monomers and 13% tetramers (Figure 2.2B). Note that
the measured mean concentration of p53 in basal conditions (397nM) was much
higher than the dimeric dissociation constant of ~ 1 nM measured in vitro. Yet
nearly 30% of p53 molecules are still monomeric, suggesting that additional fac-
tors control p53 dimer formation in cells. After DNA damage, the distribution of
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27Figure 2.3: Controls for the measurement of the brightness by FCS. A. The rela-
tive brightness of wild-type p53 calculated by photon counting histogram (PCH)
technique at rest and 3 hours after DNA damage (mean +/- SEM, n = 5) shows
the same behavior as the molecular brightness calculated by FCS (wt in Fig. 1C).
B-C. Particle brightness of single TFP and tandem dimer TFP in cell lysates mea-
sured by FCS and PCH. Each dot corresponds to a ﬂuorescent measurement and
the grey line is the sample average. D. Comparison of ﬂuorescence intensity of
sample cells expression p53-mCerulean and control cells not expressing the ﬂuo-
rescent reporter (grey line represents the sample average). E. FCS analysis of two
control cells not expressing the ﬂuorescent reporter. The background signal does
not show any autocorrelation. F. Photobleaching was minimal for all the cell lines
used, expressing either p53 wild-type or p53 mutants L344A and L344P, in 5 con-
secutive measurements (mean and standard deviation, n = 25 for p53 wild-type,
n = 20 for p53 L344A and n = 15 for p53 L344P). The red line represents the 0.9
intensity normalized by the ﬁrst measurement. G. Photon counting distribution
of a sample cell 3 hours after DNA damage with binning of 1 ms.
p53 stoichiometry drastically changed (Figure 2.2A and B): most p53 was bound in
tetramers with only a small fraction of p53 dimers and monomers. This provides
experimental evidence that DNA damage changes the balance of p53 oligomeric
state in cells, pushing it toward higher order complexes.
2.2.2 After DNA damage p53 tetramerization precedes protein accumulation .
To capture the timing of oligomerization and the relationship with total p53 lev-
els we induced DNA damage and followed both measures in individual cells over
time. The total p53 protein (as reported by ﬂuorescence intensity) slowly increases
after damage due to stabilization of the protein rather than increased expression
[98]. p53oligomerization(reportedbytheparticlebrightness)increasesmorerapidly
during the ﬁrst 90 minutes, followed by a moderate continuous increase, suggest-
ing that oligomerization precedes stabilization (Figure 2.4A and B). This order of
events is clearly captured when plotting p53 oligomerization against total levels in
each cell (Figure 2.4C).
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Figure 2.4: Dynamics of total and oligomeric p53 A. Dynamics of total p53 (orange
lines) and B. dynamics of oligomeric p53 (blue lines) post DNA damage. Each
trajectory is a single cell. The bold line is the average corresponding behavior. C.
Scatter plot of data in panels A and B. Each dot is one single-cell measurement
at the indicated time after DNA damage. Note that in the ﬁrst 90 minutes af-
ter DNA damage, cells mainly move vertically in the scatter plot, indicating that
oligomerization increases while total p53 does not change. In the following 90
minutes (180 min post damage) cells mostly move horizontally indicating that
now the concentration of p53 increases with a minimal change in the oligomer-
ization state.
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Figure 2.5: Correlation of total and oligomeric p53 during the time course. A.
Cell-to-cell variation of total and oligomeric p53. Note that the coefﬁcient of vari-
ation (CV) for total p53 does not change post damage, meaning that the variation
between cells is constant. In contrast, the CV of oligomeric p53 decreases, denot-
ing that cell-to-cell variation is reduced after DNA damage. B. The correlation
between each time point post damage and basal conditions. Lower correlation
values mean lower dependency between pre- and post DNA damage. The low
correlation of oligomeric p53 by 90 min post damage indicates that all cells con-
verge into a similar state independently of their initial state.
30We observed two additional differences between the dynamics of p53 levels and
the oligomeric state of p53 after DNA damage. First, the cell-to-cell variation in p53
total levels remains constant, while the variation in oligomeric state decreases with
time after damage (Figure 2.5A). Second, the accumulation in p53 total levels after
DNAdamagewasproportionaltothebasallevelineachcell(Figure2.5B),meaning
thatforthep53proteinlevelstheinitialstateofthecellsaffectsitsstate3hoursafter
damage. In contrast, by 90 minutes after DNA damage the extent of oligomeriza-
tion was uncorrelated with the oligomeric states in basal conditions (Figure 2.5B).
Taken together this suggests that cells with widely different oligomerization state
converge to a common proﬁle of predominantly tetrameric p53 (>90%, Figure 2.2B)
following DNA damage.
2.2.3 Higher order p53 oligomers are degraded faster
What can explain the rapid tetramerization of p53 after DNA damaged followed
by a delayed accumulation of the p53 protein? One possibility is that tetramer-
ization itself is the mechanism through which the total p53 protein is stabilized.
This would imply that the half-life of p53 tetramers should be higher than that of
p53 dimers and monomers. We measured the half-life of p53 wild-type and the
p53 mutants L344A and L344P in population and single cells (Figure 2.6). Surpris-
ingly we found the opposite trend; monomeric p53 showed the longest half-life
and wild-type p53 the shortest. Thus, the oligomerization of p53 does not con-
tribute to the stabilization of the protein. The fact that total p53 increases despite
the formation of less stable complexes appeared counterintuitive, and we therefore
sought to develop a quantitative framework to explore the relationship between
oligomerization and stabilization.
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Figure 2.6: p53 tetramers are less stable than dimers and monomers. Cells ex-
pressing wild-type or mutated p53 were treated with 10 mg/mL cycloheximide
and p53 levels were measured using immunoblots A-B and live cell imaging C-
D. The p53 half-lives displayed in panel B were calculated by ﬁtting a log-linear
decay curve to the quantiﬁcation of the blots.
322.2.4 The rapid surge of p53 tetramers requires active induction of tetramerization to-
gether with a decrease in degradation
We constructed a mathematical model including three species of p53, correspond-
ing to the three possible oligomeric states (Figure 2.7A). Monomers of p53, M, are
produced at a constant rate a and form dimers, D, and successively tetramers T.
Each species is degraded at a different rate, bm, bd, and bt, respectively. We used
the data shown in Figures 2.1-2.6 to constrain the parameter values for cells at rest-
ing conditions (see Materials and Methods, Mathematical Modeling and Parameter
Search section). We then modeled the effect of DNA damage on the system in sev-
eral alternative ways and compared each output with the experimental data.
When we modeled DNA damage only as a decrease in p53 degradation by alter-
ing the values of b’s, our model predicted a faster increase in total p53 levels than in
its oligomeric state (Figure 2.7B). Such behavior was inconsistent with our experi-
mental ﬁndings (Figure 2.4 and 2.7C). DNA damage modeled only as an induction
of p53 tetramerization (by modifying ktet
on and ktet
of f) led to a decrease in total p53
levels (Figure 2.7B), which also did not match the experimental data. Only when
we modeled DNA damage as a combination of the two effects, decrease in degra-
dation and induction of tetramerization, did the modeled dynamics agree with the
measureddynamics(Figure2.7BandC).Importantlythefastincreaseinoligomeric
p53 in the model did not depend on the speciﬁc choice of parameters (Figure 2.8
and the Methods Section for model parameterization). We concluded that both in-
duction of oligomerization and protein stabilization are required for the observed
pattern of rapid surge of p53 oligomers after DNA damage followed by increase in
total p53 levels.
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Figure 2.7: Mathematical model and simulation of p53 tetramerization and
degradation. A. The model includes three species of p53: monomers M, dimers,
D and tetramers T. p53 monomers are produced at rate a and molecules can bind
and unbind to form homo-oligomers. Each oligomeric form of p53 can be de-
graded at rate bi. B. Model simulation for the dynamics of total and oligomeric
p53 after DNA damage, modeled in 3 ways: a decrease in p53 degradation (left
panel), an increase in oligomerization (middle panel) or a combination of both
effects (right panel). C. FCS Experimental data showing total and oligomeric p53
(mean and SEM, n = 18).
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Figure 2.8: The requirement for DNA damage to induce oligomerization directly
is independent of the parameter set chosen. The model was run for all the 349
parameter sets that match the experimental data at time 0. A. If DNA damage
is modeled only as a reduction in p53 protein degradation, the ratio of particle
brightness over total intensity remains below 1 independently of the parameters
chosen. Hence oligomeric p53 cannot increase more than the total intensity. B.
If DNA damage is modeled both as a reduction in p53 protein degradation and
as an increase in p53 tetramerization, there is an initial window of time in which
oligomeric p53 increases more than the total p53. This was the case for all the
parameter sets tested.
352.2.5 Assembly of p53 tetramers does not require increase in concentration and is suf-
ﬁcient for activating p53 transcriptional targets.
Our result supports the existence of a mechanism induced by DNA damage that
directly triggers p53 tetramerization independently of its total levels. p53 lev-
els are primarily regulated by degradation, with new molecules constantly being
made and degraded. We therefore asked whether tetramerization requires syn-
thesis of new p53 molecules, or whether tetramers can be immediately assembled
from existing molecules. Our model predicts that inhibition of protein synthesis
in the absence of DNA damage should lead to a decrease in both p53 total level
and oligomerization level (Figure 2.9A). After DNA damage is applied, total p53
protein should keep decreasing while the levels of tetrameric p53 should increase.
Our experimental FCS measurements matched these predictions; oligomeric p53
increased after DNA damage even when synthesis was inhibited. We therefore
conclude that existing molecules of p53 can be assembled into tetramers.
Is the assembly of p53 tetramers sufﬁcient to induce p53 transcriptional activity?
This was previously impossible to determine since the extent of tetramerization
in cells was unknown and tetramer formation was thought to be a direct result of
the increase in total p53 concentration. Since we can now separate the increase in
total p53 levels from the increase in p53 tetramers (Figure 2.9B), we can assess the
effect of tetramerization on p53 transcriptional activity independent of the increase
in its total level. We observed that p53 targets were induced after DNA damage
even when p53 levels decreased (Figure 2.9C). Such induction was not observed
when we used a cell line expressing the oligomerization mutant p53 L344A, which
forms dimers but not tetramers. These results suggest that tetramerization of p53
is sufﬁcient to activate transcription, without an increase in total p53 protein.
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Figure 2.9: p53 tetramerization is sufﬁcient for triggering target gene activation
without an increase in p53 levels. A. Model simulation of total (orange line)
and oligomeric (blue line) p53 after translation inhibition (t = 0), followed by
DNA damage. B. Experimental conﬁrmation of the model simulation (mean and
standard error, n=6). C. p53 transcriptional targets were measured using qPCR in
response to DNA damage (NCS) and translation inhibition (CHX) for both wild-
type p53 and dimeric mutant p53 L344A. Combination of CHX and NCS leads
to an increase in the expression of p53 target genes even when p53 levels are not
induced. Induction of p53 target genes is not seen under these conditions for the
p53 L344A mutant that can form dimers but not tetramers, suggesting that the
induction of p53 targets depends on p53 ability to tetramerize.
372.3 CONCLUSIONS
Our results indicate that p53 homo-oligomerization in cells is a highly regulated
process. The balance between monomers, dimers and tetramers is not simply de-
termined by the concentration of p53 molecules. Stress responses, such DNA dam-
age, can trigger p53 tetramerization even when the protein concentration does not
increase.
Our study highlights the importance of studying protein homo-oligomerization
in cells, where the effects of post-translational modiﬁcations and co-factors mod-
ulating oligomerization can be evaluated. Several co-factors have already been
shown to regulate p53 oligomerization in vitro. For example, S100 proteins were
shown to preferentially bind p53 monomers and inhibit oligomerization [99], and
p53phosphorylationwasshowntodecreaseitstetramericKd throughbindingwith
14-3-3sv [57]. In addition, p53 binding to speciﬁc DNA was suggested to enhance
tetramerization [56]. Therefore, modiﬁcations that increase p53 binding to DNA
could have an indirect effect on the oligomerization state of p53. However even
the effects of the known co-factors on the in vitro Kd for p53 tetramerization can-
not explain the extent of tetramer concentrations we observed in cells following
DNA damage, suggesting the existence of additional unknown regulators of p53
oligomerization. Since our results demonstrate that p53’s activity as a transcription
factor can be triggered by induction of tetramerization, identiﬁcation of these un-
known factors may point to new targets for modulating p53’s function in cancer.
The approach we used here should be of general utility in studying the quantita-
tive dynamics and function of oligomerization of transcription factors and other
proteins in any cellular system [100].
382.4 MATERIALS AND METHODS
Cell line construction
The cell line MCF7+p53shRNA was kindly provided by Reuven Agami group [97],
Netherlands Cancer Institute, Amsterdam, Netherlands. cDNA for p53 was al-
tered by site-directed mutagenesis (QuikChange kit, Stratagene) at residue 344 to
obtain oligomerization mutants p53 L344A and p53 L344P, and with 7 silent point
mutations that allow for mRNA to escape shRNA silencing without altering the
amino acid sequence. p53 was expressed under the EF1a promoter and tagged
with mCerulean. The vector was introduced in cells via lentiviral infection and
stable clonal selection. Lentiviral particles were produced in 293T cells. The ﬂuo-
rescent protein mCerulean has maturation time comparable to Venus [101] which
matures in less than 10 minutes at 37 Celsius degrees [102].
Cell culture, DNA damage, and cycloheximide treatment
MCF7+p53shRNA+p53-mCerulean cells were maintained in RPMI supplemented
with10%fetalcalfserum, 100U/mlpenicillin, 100mg/mlstreptomycin, 250ng/ml
fungizone(GeminiBio-Products)supplementedwithselectiveantibiotics(400mg/ml
G418 and 0.5 mg/ml puromycin). DNA damage was induced by neocarzinostatin
(NCS,Sigma)at400ng/mLﬁnalconcentration. Translationinhibitionwasinduced
by cycloheximide (Sigma) at ﬁnal concentrations of 10 mg/mL for Figure 2.6 and
1mg/mL for Figure 2.9. Cells were harvested for protein/RNA extraction at the
indicated times after DNA damage and/or translation inhibition.
Western Blot Analysis
Harvested cells were lysed in the presence of protease and deacetylase inhibitors.
Total protein levels were quantiﬁed using the BCA assay (Pierce). Equal protein
39amounts were separated by electrophoreses on 4%–12% Bis-Tris gradient gels (In-
vitrogen) and transferred to PVDF membranes by electroblotting. Membranes
were blocked with 5% nonfat dried milk, incubated overnight with primary anti-
body, washed, incubated with secondary antibody coupled to peroxidase. Protein
levels were detected with chemoluminiscence (ECL plus, Amersham). p53 dynam-
ics were quantiﬁed by normalizing total p53 levels (DO1, Santa Cruz) to A-actin
(Sigma).
Target gene expression dynamics
Total RNA was extracted using the RNeasy protocol (Qiagen). RNA concentra-
tion was determined by measuring absorbance at 260 nm. Equal RNA levels were
used to generate complementary DNA using the high-capacity cDNA reverse tran-
scription protocol (Applied Biosystems). Quantitative PCR was performed using
reaction mixtures of 8.4 ng total RNA, 100 nM primer, and SYBR Green reagent
(Applied Biosystems).
FCS measurements and analysis
Two days before microscopy, cells were grown on poly-D-lysinecoated gridded
glass-bottom plates (MatTek Corporation). Multiphoton FCS was carried out on
a custom built setup based on a Nikon TE2000 microscope. For ECFP excitation, a
collimated 850nm IR laser beam (Mai Tai, Ti:Sapphire laser with 80MHz and 100 fs
pulse width, Spectra-Physics, CA, USA) was aligned into Nikon 100X Plan Apoc-
hromat oil immersion objective (N.A.=1.4) with back aperture slightly overﬁlled,
creating a diffraction-limited focal spot. The laser power was controlled below
2 mW to avoid photobleaching of the fusion protein, cellular photodamage and
DNA damage. The collected ﬂuorescence was passed through band-pass ﬁlters
(HQ485/70m-2p for Cerulean (Chroma Tech) and focused onto a photomultiplier
40tube (H7421, Hamamatsu, Japan). The cells were maintained in an aluminum
chamber [103] with temperature-controlled water circulation system set to 37 Cel-
sius degree. Each autocorrelation curve measured in nucleus were collected for 30
seconds using Flex02-01D/C correlator (correlator.com) and transferred to a per-
sonal computer through a high speed USB port. The PMT dead time is 70ns and
the correlator dead time is 1.56ns. The frequency of photon counts was always less
than 20 kHz, corresponding to a ﬂow of 2x10-5 photon counts per nano-second, far
from the saturation intensity – see sample histogram of photon counts distribution
in Figure 2.3G. For average purpose, ﬁve FCS curves were recorded at each posi-
tion in single cell at each time point buffering non-recurrent kinetics such as the
ones caused by extremely slow moving particles. All FCS curves were analyzed
by custom-written Matlab code (Mathworks Inc, Waltham, MA) using a nonlin-
ear least-squares ﬁtting algorithm from the curve ﬁtting toolbox (2011). The ﬁtting
formula for single-component diffusion is adapted from [104]:
G(t) = 1
<N>(1+ t
tD) 1(1+ t
w2tD)  1
2,
where <N> is the average particle number of species in the sampling volume.
tD is the residence time of species within the sampling volume, with tD = w2 xy
8D ,
where D is the diffusion coefﬁcient of the species, and w = wz
wxy is the aspect ratio of
the sampling volume. Before the ﬁt analysis, raw FCS autocorrelation curves were
denoised by averaging the ﬁve curves. Each averaged FCS curve was ﬁtted by the
formula above to get the diffusion property, molecule number. The brightness e
was calculated as
# =< I > G(0) = <I>
<N>
Notably, the diffusion coefﬁcient changed minimally over the course of the ex-
41periments (Figure 2.2C), and hence the molecular residence time was constant,
indicating that the particle brightness analysis is appropriate in this context [96].
Moreover, other proteins that bind p53 could change the diffusion coefﬁcient D;
however since G(0) is independent of D, such binding will not affect the calculated
brightness.
FCS brightness validation measurement in cell lysates
The acquired plasmid pmTFP was cut out and inserted into a EYFP-C1 vector by
NheI/BglII to form pmTFP-C1 vector. Tandem TFP-TFP plasmid was generated
by inserting a TFP ORF generated by PCR into the pmTFP-C1 vector by Sal1/Mfe1
into Xho1/Mfe1. 293T (human embryonic kidney) cells were seeded into 10 cm
petri dish and antibiotics were removed one day before the transfection. Tran-
sient transfection of TFP and TFP-TFP plasmid into 293T cell was carried out using
Lipofectamine LTX and PLUS reagents (Invitrogen). Total 10 mg DNA plasmid was
added with Opti-MEM media with LTX and PLUS to cells at 50% conﬂuence. Cells
wereharvestedonedayaftertransfection, pelletedandresuspendedin100mllysate
buffer (20mM HEPES, 5mM KCl, 1.5mM MgCl2 and protease inhibitors (Roche)).
The lysate incubated on ice for 30 minutes followed by centrifuge at 14k rpm 4C for
30minutes. The supernatant was further centrifuged at 40k rpm 4C for 30 minutes.
The collected supernatant was diluted in lysate buffer for FCS measurement. The
laser power was set to 10mw, a level at which no photobleaching was observed.
Time-lapse Microscopy
Twodaysbeforemicroscopy, cellsweregrownonpoly-D-lysinecoatedglass-bottom
plates (MatTek Corporation) in transparent medium supplemented with 5% fetal
calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and 250 ng/ml fungi-
zone (Gemini Bio-Products). Cells were imaged with a Nikon Eclipse Ti-inverted
42Table 2.1: Mathematical model equations. Ordinary differential equations used to
model the dynamics of p53 oligomerization, from monomeric p53 (M) to dimeric
(D) and tetrameric p53 (T). A full description of the parameters is given in Table
S2.
Variable Differential Equations
M = monomers of p53 dM
dt = a   2kdim
on  M
2
+ 2kdim
of f  D   bm  M
D = dimers of p53
dD
dt = kdim
on  M
2
  kdim
of f  D   2ktet
on  D
2
+ 2ktet
of f 
T   bd  D
T = tetramers of p53 dT
dt = ktet
on  D
2
  ktet
of f  T   bt  T
ﬂuorescence microscope on which the stage was surrounded by an enclosure to
maintain constant temperature, CO2 concentration, and humidity. Images were ac-
quired every 15 min. The CFP ﬁlter set was 436/20nm excitation, 455nm dichroic
beam splitter, and 480/40nm emission (Chroma). We analyzed images using Meta-
Morphsoftware(MolecularDevices)andcustomwrittenMATLABsoftware(Math-
works), which is available upon request.
Mathematical Modeling and Parameter search
The model for p53 oligomerization consists of three ordinary differential equations,
Table 2.1, with 8 parameters listed in Table 2.2. Because of the lack of experimental
techniques capable of measuring tetramerization in vivo, most of the parameters of
the model are not available in the literature. Table 2.3 includes a list of relevant
biophysical measurements available in the literature or measured in this work.
Our goal is to identify a global pattern of behavior independent of parameter
sets. The model is therefore non-dimensional, meaning that the variables and the
parameter values are unit-less. Comparison of model parameters to known ex-
perimental values (Table 2.3) would require deﬁning scales for concentration and
time, arbitrarily chosen and potentially misleading. Furthermore a ﬁtting proce-
dure could have provided us with the parameter sets that best described the data.
43Table 2.2: Parameters of the mathematical model. In the initial analysis all pa-
rameters were allowed to span a range of 7 orders of magnitude. The choice of
parameters is described in the Materials and Methods section.
Parameter
symbol
Description
a
production rate of p53
molecules
kdim
on
dimerization reaction
on-rate
kdim
of f
dimerization reaction
off-rate
ktet
on
tetramerization reaction
on-rate
ktet
of f
tetramerization reaction
off-rate
bm
monomeric p53
degradation rate
bd
dimeric p53 degradation
rate
bt
tetrameric p53
degradation rate
44However we decided against ﬁtting our model to the data because the degrees
of freedom of the parameters outweighed the constraints our data could pose on
them. This would result in multiple solutions for the parameter space without a
clear way of testing which solution would be more appropriate.
Instead we kept the values of each parameter equal to a power of 10, i.e. hav-
ing every step change in parameter correspond to one order of magnitude. We
then used the data collected from the FCS measurement on the cell line expressing
p53wt-mCerulean before stress as described below:
1. we ﬁrst allowed each parameter to attain the each of 7 possible parameter
values, 10i, where i= -3,-2,-1,0,+1,+2,+3, spanning 7 orders of magnitude; this
created a combinatorial set of over 5 million possible parameter sets,
2. we derived analytically the steady state solutions of the ODE’s in Table 2.1
and we calculated the steady state values for the 3 species of p53 for each
parameter set,
3. we narrowed down the plausible parameters sets using 3 measurements:
a) the brightness of wild-type p53 at time 0, from Figure 2.2A, +/- 5%
b) theDimer/MonomersandTetramers/Monomersratios, fromFigure2.2B
+/- 50%
c) requiring that bt > bd > bm from Figure 2.6.
Using these criteria we narrowed down the parameter space to 349 sets. Figure 2.8
shows that a combined effect, of both degradation decrease and oligomerization
increase, is required to match the trend in the experimental evidence (Figure 2.7C)
independent of parameter values.
45Table 2.3: Experimentally tested parameters. Table of biophysical experimental
measurements and their corresponding model parameters.
Physical
Parameter
Description
Model
Parameter
Value Source
Kd
Mono-Dim
Dissociation
constant of
dimerization
reaction
kdim
of f/kdim
on
~ 0.55
nM
[53]
Kd Dim-Tet
Dissociation
constant of
tetramerization
reaction
ktet
of f/ktet
on
100nM -
1mM
[57][56]
thalf
monomer
Half-life of
monomeric p53
1/bm
~1000
min
Figure 2.6
To model the perturbations caused by DNA damage we modiﬁed the corre-
sponding parameters: bm, bd and bt for changes in degradation, ktet
on and ktet
of f for
changes in the tetramerization reaction. We attempted both step changes, linear
and exponential decays for both reduction in degradation and the stabilization of
tetramerization. Qualitatively the main conclusion from the model holds true un-
der all types of perturbations of the model we tested, clearly with quantitative
differences in overall timescale of simulation and magnitude of total p53 increase
(in fact as Figure 2.8 shows even with the same type of perturbation, different pa-
rameter sets have faster dynamics than others). For Figure 2.7 and Figure 2.8 the
degradation decay is simulated as an exponential decay. The degradation rates
of all three species of p53 (monomeric, dimeric and tetrameric) were lowered by
the same proportion, hence keeping the ratios between degradation constants the
same as before damage. The stabilization of tetramerization is modeled as a linear
decrease in tetramerization off-rate and linear increase in tetramerization on-rate.
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maintains constant rate of p53
tetramerization in response to
DNA damage
The dynamics of the tumor suppressor protein p53 have been previously inves-
tigated in single cells using ﬂuorescently tagged p53. Such an approach reports
on the total abundance of p53 but does not provide a measure for functional
p53. We used bimolecular ﬂuorescence complementation to quantify in single
cells the dynamics of p53 tetramers, the functional units of p53. We found that
while total p53 increases proportionally to the input strength, p53 tetramers are
formed in cells at a constant rate. This breaks the linear input-output relation
and dampens the p53 response. Disruption of the p53-binding protein ARC led
to a dose-dependent rate of tetramers formation, resulting in enhanced tetramer-
ization and induction of p53 target genes. Our work suggests that constraining
the p53 response in face of variable inputs may protect cells from committing to
terminal outcomes and highlights the importance of quantifying the active form
of signaling molecules in single cells.
493.1 INTRODUCTION
Biological systems often exhibit a graded response in which the stronger the in-
put the higher and broader the output. However, in some systems the output is
constrained through feed-forward motifs or feedback loops, buffering against ﬂuc-
tuations or extreme signals [105, 106, 107]. Restriction of the output can also be
achieved by a rate limiting activator not affected by the input (“A” in Figure 3.1).
Alternatively constant activation in face of variable input strengths can result from
an inhibitory mechanism. In this scenario the activation is constrained by a tunable
valve, the function of which increases with the input strength (“I” in Figure 3.1).
Such a mechanism, referred to as a throttle, is commonly used in engineering. In
order to identify and characterize such potential mechanisms in biology we need
to be able to accurately measure both the total level of a signaling protein and its
active form in the same cell in response to variable input strength. Here we quan-
tiﬁed the total protein level of the tumor suppressor p53 and its active tetrameric
form in single cells in response to a range of UV doses, and identiﬁed a throttling
mechanism for damping p53 activity at high UV levels.
The p53 protein is induced in response to stress and triggers different cellular
outcomes including cell cycle arrest, apoptosis and senescence [108]. Fluorescence
reporters of p53 have previously been used to study the dynamics of p53 in live
cells [32, 35, 36]. These studies revealed that p53 dynamics depend on the stimulus
and carry information that determines cellular outcomes. UV radiation for exam-
ple, leads to a transient increase in p53 protein level displaying a single graded
pulse. The amplitude and duration of the pulse depend on the UV dose, with
higher doses leading to stronger and longer p53 induction [33] and to cell death
[22]. However, ﬂuorescently tagged p53 reports only for the dynamics of total p53,
50No Control
Signal Strength
Rate Limiting
Activator (A)
A A
Tunable
Inhibitor (I)
I I
inactive active
Figure 3.1: Signalling control strategies. Schematic drawing of potential mecha-
nisms constraining the levels of an active molecule. In all cases, the levels of an
inactive molecule (red) are proportional to the signal strength. In the absence of a
control system (top) the levels of the active form (green) are also proportional to
the signal strength. The linear relationship between signal strength and molecule
activation can be broken either by the presence of a constant activator “A”, which
limits the rate of activation (middle) or by the presence of a tunable inhibitor “I”
the strength of which depends on the strength of the signal (bottom).
51and does not capture the dynamics of active p53, which depends on speciﬁc modi-
ﬁcations and homo-oligomerization.
Activity of transcription factors in single cells can be quantiﬁed using various
methods. In cases where the transcription factor is regulated through localization
ﬂuorescent tagging was used to report for transcriptional activity [109, 110]. p53
is stably localized in the nucleus and therefore localization is not a sufﬁcient mea-
sure for its activity. Transcription factors’ activity in cells can also be measured by
a transcriptional reporter, in which a target gene promoter drives the expression of
a ﬂuorescent protein. Such an approach has been used, for example, to study the
activity of the circadian clock gene Per1 [111] and the dynamics of ComK, the ‘mas-
ter’ transcription factor of genes necessary for competence in Bacillus subtilis [112].
In the p53 pathway different target genes show different patterns of activation, im-
plying that their induction depends on additional factors beyond p53 and making
it impossible to choose a single promoter as a general readout for p53 activity [22].
Tetramerization of p53 has been shown to be fundamental for its ability to bind
DNA and activate transcription, suggesting tetramerization as a valuable measure
for globally quantifying the functional unit of p53 in single cells. The formation
of p53 tetramers is driven by a C-terminal tetramerization domain. The reaction
proceeds in two steps: ﬁrst p53 monomers bind into dimers, which then form
tetramers. Importantly the tetrameric binding interface only forms when dimer-
ization has occurred, hence p53 tetramers are referred to as “dimers of dimers”.
Previous in vitro work showed that p53 dimerization occurs co-translationally, on
the polysome, suggesting that p53 dimers are composed of monomers translated
fromthesamemRNA[55]. Furthermorep53wassuggestedtobeprimarilydimeric
in cells, as the dimer dissociation constant is in the order of 10-4 µM [53, 56], several
orders of magnitude lower than p53 cellular concentration (~0.1-10µM). Tetramer-
52ization occurs post-translationally with a much higher Kd of ~1µM, which can be
altered by post-translational modiﬁcations and co-factor binding [67, 57, 94]. Muta-
tions in the p53 tetramerization domain (326-356 aa) lead to a reduction in, or loss
of, its transcriptional activity in cells [68] and were shown to cause early cancer
onset, known as Li-Fraumeni syndrome [70, 74].
In Chapter 2 we used ﬂuorescence correlation spectroscopy (FCS) to measure the
tetramerization of p53 in single cells [113]. This method allowed quantifying the
stoichiometry of p53 oligomers directly in live cells and monitoring their tempo-
ral changes after DNA damage. However, FCS is a low-throughput method; the
number of cells measurable by FCS is limited (~5-20) and the single cell dynamics
can currently only be measured manually. Here we developed a bimolecular ﬂuo-
rescence complementation (BiFC) assay to quantify the dynamics of p53 tetramers
in single cells and investigated how cells regulate total p53 and its activity under
various input strength.
3.2 RESULTS
3.2.1 BiFC captures p53 tetramerization in single cells
To investigate the dynamics of p53 oligomerization in cells we used bimolecular
ﬂuorescence complementation (BiFC). BiFC relies on splitting a ﬂuorescent protein
in two complementary fragments, and tagging each to one of two proteins that po-
tentially bind each other. The split fragments are not ﬂuorescent alone and bind
each other with low afﬁnity. When they are brought together by the stable interac-
tion of the proteins they are tagged to, the full ﬂuorescent protein is able to form
leading to a ﬂuorescent signal (Figure 3.2A and [90, 91, 114]).
We tagged two copies of p53 to two different halves of YFP (YFP-N or YFP-C)
and stably expressed them in human cells. Each p53 was also tagged to a full-
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54Figure 3.2: BiFC reports for p53 tetramerization A. BiFC is based on tagging pu-
tative interactive proteins (“A” and “B”) with two different fragments of a ﬂuo-
rescence protein (“n” and “c”). The interaction between A and B brings the non-
ﬂuorescent fragments in close proximity and they form a full ﬂuorescent protein.
B. Schematic drawing of the p53 reporters. C. Schematic drawing of the various
p53 species; p53 L344A forms dimers but not tetramers while p53 L344P is fully
monomeric, since it is not able to form dimers or tetramers. D. Images of cells
expressing the constructs in panel B with mutant or wild-type p53 in bright-ﬁeld
illumination, RFP and YFP. All cells show the RFP signal (total p53), but only the
cells expressing wild-type p53 show YFP signal (p53 tetramers). E. Ratio of YFP
to RFP ﬂuorescence level in cells. Mean and standard deviation are reported and
values are normalized to p53 L344P sample. N > 50 for each condition. F. p53
forms homo-dimers, in which both monomers are tagged with the same frag-
ment of YFP leading to no YFP signal. When two dimers form tetramers the split
YFP protein is formed and becomes ﬂuorescent.
Figure 3.3: Co-immunoprecipitation of biochemically tagged p53. A. p53 was
tagged with biochemical tags HA and CFP and expressed in cells. B. Co-
immunoprecipitation experiment in cells expressing wild-type p53-CFP together
with either mutant or wild-type p53-HA. Cells were damaged with the ra-
diomimetic drug NCS and lysates were collected 2.5 hours after treatment.
When wild-type p53-HA is pulled-down, p53-CFP co-precipitates, indicating
that hetero-oligomers are formed. When the “dimers only” mutant p53 (L344A-
HA)orfullymonomericmutantp53(L344P-HA)areexpressedandpulleddown,
p53-CFP does not co-precipitate, indicating that no heterodimers are present in
cells.
55length red ﬂuorescence protein (RFP) to report for the total p53 protein in cells
(Figure 3.2B). In principle, the formation of both p53 dimers and tetramers could
yield ﬂuorescence. In order to separate the contribution of each of these states to
our measurements we used two well-characterized mutants of p53; p53 L344A that
forms dimers but not tetramers, and p53 L344P, which is exclusively monomeric
(Figure 3.2C). As expected, the p53 L344P monomeric mutant showed extremely
low YFP signal (Figure 3.2D), representing auto-ﬂuorescence or unspeciﬁc binding
between the YFP fragments. Notably, the p53 L344A mutant that is able to form
dimers did not display higher YFP ﬂuorescence than the monomeric mutant (Fig-
ure 3.2D). Accordingly the ratio between the YFP signal to total p53 (measured by
the RFP signal) in the L334A mutant was equivalent to the ratio obtained from the
monomeric mutant L334P (Figure 3.2E), conﬁrming that dimerization of p53 does
not add ﬂuorescence signal beyond the background observed by the monomeric
p53. This suggests that p53 dimers are homo-dimers, meaning every dimer com-
prises the same two halves of YFP (Figure 3.2F). This is in agreement with recent
in-vitro studies showing that p53 dimers are formed co-translationally, consisting
of two monomers translated from the same mRNA [55]. Once formed the dimers’
low dissociation rate and the short half-life of p53 keeps dimers from exchanging
monomers.
Wefurtherconﬁrmedthehomo-dimerizationofp53byapull-downassayofcells
expressing two p53s fused to HA or CFP (Figure 3.3). This biochemical assay con-
ﬁrmed that in cells p53 dimers are indeed homo-dimers and that hetero-oligomers
are formed only at the level of tetramers. The lack of p53 hetero-dimers and the in-
creased YFP signal obtained from wild-type p53 (Figure 3.2D and E) indicates that
the BiFC experimental setup is suitable for quantifying the level of p53 tetramer-
ization in single cells (Figure 3.2F).
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Figure 3.4: Time lapse images and quantiﬁcation of total and tetrameric p53 af-
ter UV. A. Sample time lapse images of a ﬁeld of cells following 6 J/m2 UV. B.
Quantiﬁcation of nuclear ﬂuoresence in single cells after 6 J/m2 UV. Each trace is
a single cell. Bold traces represent the mean dynamics (n = 100).
573.2.2 Formation of p53 tetramers is damped at increasing UV doses
Images of cells expressing the p53 tetramer reporter revealed that UV irradiation
triggers a transient single pulse of p53 tetramers, similar to the dynamics observed
for total p53 (Figure 3.4). However, when we treated cells with a range of UV doses
we observed a major difference between the dynamics of total p53 and tetrameric
p53. Higher doses of UV led to an increase in the amount of total p53 as was previ-
ously reported [33]. p53 tetramers also showed higher levels with higher UV doses,
however the effect was limited in comparison to total p53 (Figure 3.5A). Quantita-
tively, the ratio between p53 tetramers and total p53 decreases with higher levels
of UV, indicating damping of p53 tetramers (Figure 3.5B). To quantify the damping
in single cells we plotted the peak levels of total and tetrameric p53 in each cell
(Figure 3.5C). At a low UV dose (3 J/m2) the peak levels were linearly correlated
(red line). If tetramerization follows total p53 levels linearly, one would expect both
the RFP and YFP signal to increase proportionally and to follow the red line under
various UV doses. Instead, at a high UV dose (12 J/m2) cells shifted to the right of
the red line in the scatter plot, indicating that the increase in tetramerization does
not match the increase in total p53.
3.2.3 p53 tetramers are formed at a constant rate independent of input strength
We next asked what leads to the damping of p53 tetramers in response to high lev-
els of UV. The dynamics of p53 post UV can be described by two main properties:
the rise time, which is the duration of the increase; and the slope, which is the rate
at which the signal accumulates (Figure 3.6A). The damping in the ratio between
p53 tetramers and total p53 could derive from modulation of either of these two
properties. We found that the rise time increases with higher UV doses for both to-
tal p53 and p53 tetramers (Figure 3.6B). Damping in p53 tetramers therefore cannot
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Figure 3.5: Dynamics of total and tetrameric p53 after increasing doses of UV. A.
Time traces of the mean ﬂuorescent level under three doses of UV irradiation.
Red traces represent total p53 and green represent tetrameric p53 levels. Traces
were normalized to the respective maximum level of 3 J/m2 UV treatment (n =
280). B. The ratio of p53 max levels, attained by YFP, over its max tetrameric
levels, attained by RFP. Error bars represent standard deviation of the mean. p-
values calculated by Mann-Whitney test. C. Scatter plot of the RFP peak versus
the YFP peak after 3 and 12 J/m2 UV. Each dot represents one cell. The red line
represents the ﬁt obtained from cells following 3 J/m2, and is presented at 12
J/m2 as a reference to compare the distributions between damage levels.
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60Figure 3.6: The rate of p53 tetramers formation is constant across UV doses. A.
The dynamics of p53 after UV can be captured by two main parameters: the
rise time and the slope of increase. B-C. Rise time (B) and slope (C) for total
and tetrameric p53 at increasing doses of UV. Shown are median and SEM. n =
210. p-values were calculated by Mann-Whitney test, with p=0.05 as signiﬁcance
threshold. D. Scatter plots of the slope of oligomeric versus total p53 after 3 and
12 J/m2 UV. Each dot represents one cell. The red line represents the ﬁt obtained
from cells following 3 J/m2, and is presented at 12 J/m2 as a reference to compare
the distributions between damage levels. E. Schematic drawing recapitulating
the data. The rise time increases with input strength for both total and tetrameric
p53. The slope “m” increases only for total p53 (red lines) and is constant for
tetrameric p53 (green lines).
be explained by a difference in rise time. On the other hand the slope of p53 accu-
mulation showed a different behavior; the slope of total p53 was dose dependent,
however the slope of p53 tetramers was constant across all UV doses (Figure 3.6C).
This implies that p53 tetramers are formed at a constant rate, regardless of the UV
dose. Comparison of the slope at low (3 J/m2) and high (12 J/m2) UV doses in
individual cells indeed showed that even for cells that accumulate total p53 faster,
the rate at which p53 tetramers are formed is ﬁxed and does not follow the rate of
total p53 accumulation (Figure 3.6D).
If the dimer-tetramer reaction of p53 were in equilibrium, an increase in the total
protein level would result in a proportional increase in the tetrameric level. Instead
our results show that the inﬂux of tetramers is ﬁxed across input strength (Figure
3.7). A simple mass-action balance therefore cannot explain our data. The slope
conservation of p53 tetramers suggests that there is a regulatory mechanism main-
taining a constant rate of tetramer formation independent of the rate at which total
p53 accumulates.
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Figure 3.7: ARC knockdown by siRNA. A. The ARC protein binds p53 and inter-
fers with its tetramerization. B. qPCR of ARC mRNA under scrambled and ARC
siRNA, 48 hrs post trasfection. C. Immunoblot of cells following UV at the indi-
cated time points. The levels of ARC are not affected by UV. siRNA against ARC
decreases its protein levels. D. Distribution of mean nuclear ARC protein mea-
sured by immunoﬂuorescence. Knockdown of ARC by siRNA efﬁciently reduces
the amount of ARC protein across cells.
623.2.4 ARC knockdown breaks the slope conservation and leads to enhanced induction
of p53 targets
Maintaining a constant rate of tetramer formation could be achieved by sequester-
ingdimersofp53frombecomingtetramers, thereforereducingthepooloftetramers
precursor. The apoptosis repressor with caspase recruitment domain (ARC) was
previously shown to interact with p53 and disrupt its tetramerization (Figure 3.7A
and [67]). To test whether ARC is responsible for the ﬁxed rate at which p53
tetramers are formed, we silenced ARC by siRNA (Figure 3.7B, C and D) and mea-
sured the effect on total p53 and p53 tetramers in single cells. The dynamics of total
p53 were not affected by ARC knockdown (Figure 3.7B). The maximum level of to-
tal p53 in single cells and the slope of total p53 accumulation were not altered in
the absence of ARC (Figure 3.8A). Conversely, the dynamics of p53 tetramers were
signiﬁcantly affected by knockdown of ARC; p53 tetramers formed faster as indi-
cated by the increase in both the slope of tetrameric p53 post UV and the higher
maximum level (Figure 3.8B). Moreover, silencing ARC disrupted the slope con-
servation of tetramer formation across UV doses; higher doses of UV led to steeper
slope of p53 tetramers formation (Figure 3.8C) and the damping effect was lost
(Figure 3.8D).
Does breaking the ﬁxed rate of tetramer formation enhance the transcription of
p53 target genes? We measured the induction of p53 target genes after UV treat-
ment with and without ARC. We found that silencing ARC leads to a stronger
induction of p53 represented target genes involved in apoptosis and cell cycle ar-
rest (Figure 3.9A) in a p53 dependent manner (Figure 3.9B). This suggests that the
increase in the inﬂux of p53 tetramers caused by ARC knockdown boosts p53 ac-
tivity.
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Figure 3.8: ARC knockdown leads to dose-dependent rate of tetramers forma-
tion. A. Maximum levels and slope of total p53 after ARC knockdown. B. Max-
imum levels and slope of tetrameric p53 after ARC knockdown. (median and
SEM, n=170). ARC knock-down does not affect the maximum and slope of total
p53 (p = 0.62) but increases the rate of p53 tetramer accumulation (p = 0.017).
C. Knockdown of ARC breaks the slope conservation of tetramers formation
(median and SEM. n = 360). D. Dynamics of total and tetrameric p53 follow-
ing siRNA against ARC measured by BiFC after UV (time average across cells,
traces were normalized to the respective maximum level of 4.5 J/m2 UV treat-
ment, n = 180). The damping effect on p53 tetramerization is not observed in the
absence of ARC.
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Figure 3.9: ARC knockdown enhances the induction of p53 target expression in
a p53-dependent manner. qPCR of p53 target genes mRNA following 6 J/m2
UV. A. Fold induction of p53 targets after ARC siRNA. Knockdown of ARC (red)
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653.3 CONCLUSIONS
Fluorescence protein tagging allows quantiﬁcation of protein dynamics in live cells
and has provided an incredible amount of insight about the anatomy, structure and
physiologyofthecell[32,115,116]. Howevervariousfeaturesofcellularresponses,
such as post-translational modiﬁcations and oligomerization, are known to affect
protein function and are not captured by such ﬂuorescence reporters. In the case of
p53, ﬂuorescent tagging enabled quantiﬁcation of its dynamics in response to var-
ious stresses, making important links between speciﬁc inputs, p53 dynamics and
cell fate [22, 117]. However, the question how well the levels of total p53 represent
the levels of functional p53, remains elusive. Here we show that while higher UV
doses translate into higher amplitude and longer duration of total p53, the func-
tional units of p53, its tetramers, are formed in a ﬁxed rate regardless of the input
strength, leading to a damped response, and potentially buffering against large
changes in total p53.
The BiFC method we used in individual cells, together with pull-down assays in
populations of cells, conﬁrmed what has previously been suggested in-vitro [55];
that p53 dimerization occurs co-translationally, resulting in homo-dimers in which
both monomers are translated from the same mRNA. Many cancers are heterozy-
gotes for p53 and it has been suggested that mutated p53 within a tetramer can
abolish the DNA capacity of the entire complex [72, 118]. In agreement, gain of
function of p53 due to speciﬁc mutations, is not functional when the tetrameriza-
tion domain is missing [119, 120]. The fact that in cells p53 dimers are homo-dimers
indicates that in heterozygous cases the stoichiometry of wild-type and mutant p53
in a tetramer can only be 0:4, 2:2 or 4:0. In the case of a dominant negative mutant
this changes the ratio of functional and non-functional complexes, which is im-
66portant for our understanding and ability to rescue mutant p53 and enhanced its
function in cancer cells.
Constant rate of tetramers formation in face of varying UV doses can theoreti-
cally be achieved by two distinct mechanisms: (i) a rate limiting activator of p53
tetramerization, displaying ﬁxed levels and activities independent on the UV dose;
(ii) a tunable inhibitor of p53 tetramerization exhibiting stronger inhibition at high
levels of UV (Figure 3.1). Such inhibitory strategy allows for total p53 protein to
accumulate while the formation of p53 tetramers remains constraint by a tunable
valve. In mechanical engineering, such a valve is often used to regulate the ﬂow of
a ﬂuid or gas entering an engine, optimizing a desired property of the engine, such
as speed, power or fuel efﬁciency.
Variousactivatorswerepreviouslyshowntoenhancetheformationofp53tetramers,
including 14-3-3sv and Hsp70 [57, 121]. While these activators are undoubtedly im-
portant for this process, our ﬁnding that knock down of ARC allows p53 tetramers
to form faster at higher UV doses (Figure 3.9), indicates that the constant rate of
tetramers formation in the p53 systems is achieved through inhibition, and not by
a rate limiting activator (Figure 3.1). The mechanism by which ARC’s competi-
tive inhibition is tuned in response to various UV doses remains an open question.
The fact that ARC protein levels do not change after UV suggests that its func-
tion requires additional controls such as post-translation modiﬁcations or cellular
localization [122].
What could be the biological advantages of controlling p53 tetramers with a
molecular throttle constraining tetramers formation? p53 triggers crucial outcomes
in cells, some are terminal and irreversible. UV, for example leads to cell death. Ex-
ecuting such outcomes at the right time is an important feature of p53 function.
A simple linear relationship between UV dose and p53 levels can be dangerous to
67cells, as high levels of p53 can activate apoptosis too fast, without allowing cells
the time to repair the damage and recover. Fixing the rate at which tetramers are
formed disrupts the linear relationship by creating a “brake” in the formation of
functional p53, which may be required for protecting cells from prematurely com-
mitting to cell death.
A similar idea, yet through a different mechanism, has recently been proposed in
the control of DNA damaged induced senescence through p53. Gamma irradiation
leads to a series of ﬁxed p53 pulses and to temporary cell cycle arrest [22, 32]. Mod-
ulation of p53 dynamics to a sustained non-oscillatory response pushes cells into
prematurely committing to senescence. Thus, p53 pulses (in response to gamma)
or a ﬁxed rate of tetramer formation (in response to UV) are two examples of cel-
lular mechanisms breaking the linear relationship between input strength and p53
function, presumably protecting cells from committing to irreversible fates.
One of the main goals in cancer therapy is to enhance p53 function in cancer cells.
Our ability to understand the various constraints on p53 function through modu-
lation of its dynamics or inhibition of its tetramers has important implications for
inducing p53 activity in cells. Speciﬁcally, our study suggests that enhancing the
efﬁcacy of DNA-damaging drugs can be achieved by combining them with drugs
that inhibit ARC, breaking the ﬁxed rate of tetramers formations in cells. Other
pathways are known to control cell fate decisions in cells. Developing new tools
for measuring their dynamical activity in single cells can help reveal other potential
molecular throttles for properly controlling the balance between alternative cellu-
lar outcomes.
683.4 MATERIALS AND METHODS
Cell line construction
The cell line MCF7+p53shRNA was kindly provided by Reuven Agami group [97],
Netherlands Cancer Institute, Amsterdam, Netherlands. cDNA for p53 was al-
tered by site-directed mutagenesis (QuikChange kit, Stratagene) at residue 344 to
obtain oligomerization mutants p53 L344A and p53 L344P, and with 7 silent point
mutations that allow for mRNA to escape shRNA silencing without altering the
aminoacidsequence. p53wasexpressedundertheEF1apromoterandtaggedwith
the full red ﬂuorescent protein mKate2 and one of the two fragments of mVenus
(mVenus-N, 1-158aa and Venus-C, 159-240aa). The vector was introduced in cells
via lentiviral infection and stable clonal selection. Lentiviral particles were pro-
duced in 293T cells.
Cell culture and DNA damage
MCF7+p53shRNA+p53-mKate2-mVenus-N/C cells were maintained in RPMI sup-
plemented with 10% fetal calf serum, 100 U/ml penicillin, 100 mg/ml strepto-
mycin, 250 ng/ml fungizone (Gemini Bio-Products) supplemented with selective
antibiotics(400mg/mlG418, 0.5mg/mlpuromycin, 100mg/mLhygromycin). DNA
damage was induced in cells using a UV-C 254nm light source (Ushio). UV was
delivered to cells using a UV lamp with a rate of 1.5 J/m2/s. All UV treatments,
therefore, were performed in a single burst lasting < 7s. Cells were harvested for
protein/RNA extraction at the indicated times after DNA damage.
Western Blot Analysis
Harvested cells were lysed in the presence of protease and deacetylase inhibitors.
Total protein levels were quantiﬁed using the BCA assay (Pierce). Equal protein
69amounts were separated by electrophoreses on 4%–12% Bis-Tris gradient gels (In-
vitrogen) and transferred to PVDF membranes by electroblotting. Membranes
were blocked with 5% nonfat dried milk, incubated overnight with primary an-
tibody, washed, incubated with secondary antibody coupled to peroxidase. Pro-
tein levels were detected with chemoluminiscence (ECL plus, Amersham). p53
dynamics were quantiﬁed by normalizing total p53 levels (DO1, Santa Cruz) to
alpha-actin (Sigma). ARC was detected with a polyclonal antobody against ARC
(Cayman Chemical, 160737).
Target gene expression dynamics
Total RNA was extracted using the RNeasy protocol (Qiagen). RNA concentra-
tion was determined by measuring absorbance at 260 nm. Equal RNA levels were
used to generate complementary DNA using the high-capacity cDNA reverse tran-
scription protocol (Applied Biosystems). Quantitative PCR was performed using
reaction mixtures of 8.4 ng total RNA, 100 nM primer, and SYBR Green reagent
(Applied Biosystems).
Time-lapse Microscopy
Twodaysbeforemicroscopy, cellsweregrownonpoly-D-lysinecoatedglass-bottom
plates (MatTek Corporation) in transparent medium supplemented with 5% fetal
calf serum, 100 U/ml penicillin, 100 mg/ml streptomycin, and 250 ng/ml fungi-
zone (Gemini Bio-Products). Cells were imaged with a Nikon Eclipse Ti-inverted
ﬂuorescence microscope on which the stage was surrounded by an enclosure to
maintain constant temperature, CO2 concentration, and humidity. Images were ac-
quired every 15 min. The mVenus ﬁlter set was 500/20x excitation, 515nm dichroic
beam splitter, and 535/30m emission (Chroma). The mKate2 ﬁlter set was 560/40x
excitation, 585nm dichroic beam splitter, and 630/75m emission (Chroma). We an-
70alyzed images using MetaMorph software (Molecular Devices) and custom written
MATLAB software (Mathworks), which is available upon request.
RNAi
To knockdown ARC we used siGENOME SMARTpool of siRNA against the NOL3
gene mRNA (Dharmacon). For all controls we used the scrambled siRNA from
QUIAGEN (AllStars Negative Control siRNA, Qiagen 1027280). We performed all
RNA transfection using DharmaFECT 1 transfection reagent following the manu-
facturer’s protocol (Dharmacon). We assayed the knockdown of NOL3 48 hr after
transfection.
Co-Immunoprecipitation assay
MCF7 p53shRNA cells were infected with lentivirus expressing pEF1a-p53wt-CFP
and pEF1a-p53(wt/L344A/L344P)-HA and selected by antibiotic resistance. Cells
were treated with 400 ng/ml neocarzinostatin (NCS, Sigma) and collected after 2.5
hrs. Cell lysate were obtained with lysis buffer without SDS (TNTE /1% Triton
buffer supplemented with protease and phosphatase inhibitors) passing samples
through 20G needle 10X at 4°C then spun down in chilled table top centrifuge for
30min. Lysates were incubated for 1 hour at 4°C in rotating shaker with mon-
oclonal anti-HA-agarose beads (A2095, Sigma) pre-washed 3X in TNTE buffer.
Lysate-beads solutions were washed 3X in TNTE buffer then resuspended in 4X
LDS buffer and boiled at 95°C for 3 min.
Immunoﬂuorescence
Cellsweregrownoncoverslipscoatedwithpoly-L-lysineandﬁxedwith2%paraformalde-
hyde for 15 min at RT. Cells were permeabilized with 5 min incubation in 100%
methanol at -20°C, washed in PBS, incubated with primary antibody against ARC
71(Cayman Chemical, 160737), washed, and incubated with secondary antibody cou-
pled to Alexa555. After washing, cells were stained with DAPI and embedded in
Prolong Antifade (Invitrogen). Images were acquired with a 20x plan apo objective
(NA 0.75) with the CY3 ﬁlter set (sp102v1, Chroma). Automated segmentation was
performed in Matlab (MathWorks). 5,000-8,000 cells were measured per condition.
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72Chapter 4: Discussion
4.1 REACTIVATING P53 IN CELLS
Through this work I aimed to investigate the control of p53 homo-tetramerization
and to demonstrate that inducing tetramerization can trigger activation of p53
function. I used two types of DNA damage that are known to activate p53 and
have been instrumental to demonstrate the correlation between tetramerization
and transcriptional activity. This was possible as I have been able to precisely quan-
tify the amount of tetramerized p53. Moreover I started elucidating the co-factors
that regulate p53 tetramerization in cells and what their role is.
The high rate of mutations in the p53 pathway observed in cancers underscores
its importance in preventing uncontrolled proliferation. The most common alter-
ations in p53 lead to loss of its function as a transcription factor. Hence the strate-
gies that have been used to target p53 defective tumors are centered in attempting
to restore functionality. One promising approach involves increasing p53 protein
concentration by targeting its interaction with Mdm2. Such approaches led to the
development of drugs like Nutlin [123] and RITA [124]. Another approach im-
73plicates reactivating the function mutant p53 with drugs that bind the protein core
[125]. Anotherpossibilitythatemergedfrommystudiesistopushtheexistingpool
of p53 into its tetrameric conformation, and by this boosting its activity. However
the in vivo understanding of the control and function of tetramerization is limited.
The aim of this work was to develop methods for studying homo-oligomerization
in live cells and to advance the understanding of the p53 tetramerization reaction.
4.2 ADVANCEMENTS IN QUANTIFICATION OF HOMO-OLIGOMERIZATION
IN LIVE SINGLE CELLS
I developed and applied two complementary methods in this study, ﬂuorescence
correlationspectroscopy(FCS)andbimolecularﬂuorescencecomplementation(BiFC).
Both methods enable measuring total p53 protein and p53 tetramerization simulta-
neously, dynamically and in living single cells; all features that are fundamental to
study p53 tetramerization. While the mechanics of the oligomerization reaction in
isolation have been worked out in detail in vitro, in living cells co-factors and post-
translational modiﬁcation affect p53 regulation. Moreover, after cellular stress the
levels of p53 protein undergo complex dynamics that can drive the oligomerization
reaction and confound the understanding of its regulation. Hence monitoring the
tetramerization state together with its protein level is essential.
ThedifferencebetweentheFCSandtheBiFCmeasurementsconsistsinthetrade-
off between precision and time resolution. The oligomeric state of p53 spans a
small dynamic range between dimerization and tetramerization. FCS provides
adequately precise quantiﬁcation of the aggregation state to calculate the distri-
bution of p53 oligomers prior to perturbation, and dissect the molecular events
triggered by DNA damage at resolution of less than one hour. However FCS has a
low throughput, allowing the measurement of fewer than 10 cells in the same ex-
74periment for only up to a few hours. In contrast BiFC is based on epiﬂuorescence
microscopy, which allows the tracking of tens of cells simultaneously in a set of di-
verse conditions. The maturation of the reassembled ﬂuorescent proteins does not
allow for a short time resolution but the experimental setup enables following cells
for multiple days. The complementarity of these methods allowed us to study the
behavior of p53 tetramers after DNA damage caused by two sources, radiomimetic
drugs and ultraviolet radiation, which have been shown to cause different tempo-
ral dynamics of p53 protein levels.
4.3 RAPID ACTIVATION OF P53 OLIGOMERIZATION AFTER DNA DAM-
AGE
After double strand breaks (generated by IR or IR-mimicking agents) p53 shows
a digital response with pulses of protein accumulation roughly 5 hours long and
with conserved amplitude and frequency [32]. At the end of each pulse, recurrent
activation of the pathway leads to either another full pulse or no induction at all
[35]. Moreover increasing doses of damage lead to more pulses rather than modi-
fying the pulse characteristics. Even though it is unclear whether the induction of
each pulse is molecularly identical, these observations suggest that the key activa-
tion events occur in the ﬁrst couple of hours after damage. Using FCS I measured
p53 tetramerization during the induction of the ﬁrst pulse and I showed how the
formation of p53 tetramers occurs before the accumulation of p53 protein and even
in its absence. Given the higher rate of tetramers degradation, the parallel induc-
tion of tetramerization and total protein suggests the presence of speciﬁc regulation
to induce the accumulation of tetramers. Importantly I decoupled the increase of
p53 oligomers from the protein abundance and showed that the transcriptional
function of p53 is also increased just by p53 oligomerization.
75Themechanismofupregulationofp53tetramerizationafterdoublestrandbreaks
is not known. Tetramerization occurs rapidly and this strongly suggests that the
regulation is not transcriptional but rather based on co-factor binding and post-
translational modiﬁcations. In vitro studies have shown that certain modiﬁcations
can stabilize the p53 tetramers. For instance phosphorylations at residues Ser366,
Ser378andThr387leadtobindingofp53to14-3-3proteins, decreasingthetetrameric
dissociation constant by up to 10-fold [57]. Furthermore, phosphorylation at Ser392
and dephosphorylation of Ser315 directly increase p53 self-afﬁnity [58]. Other
modiﬁcations are known to require tetramerization in order to happen, such as
phosphorylation at Ser20 and C-terminal lysines acetylation [75, 126]. Applying
FCS to mutants constitutively modiﬁed, for example by phospho-mimic amino
acid substitutions, would be insightful to understand to what extent these mod-
iﬁcations affect p53 tetramerization in cells.
TheapplicationsoftheFCSmeasurementsarepotentiallyextremelybroad. Firstly
they allow to measure oligomerization in different cell compartments, thanks to the
small volume of observation relative the size of a human cell. For instance p53 is
known to relocate to the mitochondria and to induce apoptosis by inhibiting anti-
apoptotic proteins such as Bcl2 and BclX. Hence an interesting question that could
be answered with our experimental setup is whether p53 does so as a dimer or
as a tetramer. More generally this method could be used to measure aggregation
of virtually any protein in the cell. The only limitation is posed by the cellular
concentration of the protein; this needs to be low enough for the diffusion of the
molecules to and from the observation volume to produce signiﬁcant ﬂuctuations
in the ﬂuorescent intensity signal.
764.4 A MOLECULAR MECHANISM KEEPING THE RATE OF P53 TETRAMER-
IZATION CONSTANT
In contrast to the digital response to double strand break, UV induced DNA dam-
age triggers a single pulse of p53 accumulation, the height and the duration of
which are UV dose-dependent. The lengthen time scale and the need for varying
doses of UV damage made the BiFC method more suitable to study tetramerization
of p53 in this context.
First I demonstrated how dimerization of p53 is co-translational in cells, conﬁrm-
ing a feature that was previously postulated from an in vitro translation experiment
[55]. More precisely I showed that proteins expressed from different alleles of p53
do not mix at the dimer level, during or after translation. This is in agreement with
the strong dimeric binding constant measured in vitro, but it is in contrast with
other evidence showing that co-factors of p53, such as members of the S100 protein
family, are able to induce monomerization of p53 dimers in the test tube [99]. The
latter occurrence is not likely in our experiment as I performed them in MCF7 cells
that do not express these members of the S100 family. In FCS I observed a popula-
tion of freep53 monomers, but Idid not observe subunit exchangebetween dimers.
These observations suggest that once the chance to dimerize near the ribosome is
missed, then the p53 monomers remain monomeric and do not form dimers. On
top of this, the rate of dimerization likely increases after DNA damage, since the
fraction ofmonomers decreasesin time. The yetunknown mechanism that controls
co-translationality of dimerization has important implications for mutant p53, be-
cause it implies that mutations of p53 affect both proteins in every dimer. Hence in
p53 heterozygous cells the interaction between wild-type and mutated p53, which
is the basis of the dominant negative effect, occurs only at the tetrameric interface
77level.
I also showed that, while the tetramerization reaction after double strand breaks
is activated, increasing doses of UV actually dampened the binding between p53
dimers. Despite the fact that the rate of total p53 increases in parallel with the in-
crease of radiation, the system features a constant rate of tetramer formation. I en-
vision this mechanism as a tunable molecular valve, or a throttle, which constrains
the entry into the tetrameric state making it steady in spite of a varying amount of
available total p53. Since p53 transcriptional activity requires tetramerization, the
throttle steadies the transcription of target genes. However it is not intuitive why
such a constraint would be beneﬁcial, especially since increased damage does cre-
atemorestresstothecell. Onepossibilityisthattheconstantrateoftetramerization
makes p53 tetramer levels work as a timer. The steady increase of tetramers stands
for the signal being “on” and the length of the pulse, which is still dose-dependent,
reports for the time at which the signal is turned “off”. Another possibility is that
the pool of p53 dimers plays a functional role, probably not transcriptional, and
that the system is actually increasing the dimer population to enhance a speciﬁc
function, yet to be unveiled.
I observed that at increasing the doses of UV radiation the tetrameric fraction is
reduced. This suggested a negative regulation on tetramerization and I conﬁrmed
this hypothesis by identifying ARC, i.e. apoptotic repressor with CARD domain
as part of the inhibitory process. While ARC is a necessary part of the molecular
throttle, it is unlikely that it works alone, especially since ARC’s protein level does
not increase after DNA damage. Either other proteins form a complex with ARC to
inhibit tetramerization or ARC’s activity is dependent on post-translational mod-
iﬁcations that are altered after damage. By knocking-down ARC I showed that
downregulation of the throttle leads to an increase in p53 transcriptional activity.
78Moreover since ARC knockdown did not affect the p53 protein levels, this is at-
tributable speciﬁcally to the increase in tetramerization.
4.5 FUTURE DIRECTIONS
The work in this thesis highlighted novel instances of regulation of p53 function
through modulation of tetramerization. It showed that, irrespective of the levels of
p53 protein, additional factors inﬂuence tetramerization, either inducing or inhibit-
ing it. These ﬁndings open two avenues of research: to investigate the molecular
basis of these regulatory processes and to chemically alter the tetrameric balance
for possible therapeutic applications. In both cases the BiFC system described in
Chapter 3 can be employed to perform a screen to identify putative candidates,
while the FCS setup from Chapter 2 would be used to validate the screen’s hits.
The siRNA approach used to assay for ARC’s inhibition of tetramerization in
Chapter 3, can be extended into a genetic screen with pooled barcoded shRNA’s.
Two-color FACS would be used to isolate the population of cells with highest
tetrameric p53 levels, relative to the total p53 amount, which would then be ana-
lyzedbynext-generationsequencingtorecoverthepotentialhits. Thisassaywould
unbiasedly probe for other negative regulators of p53 tetramerization. However,
since there are a number of putative p53 cofactors already known, a global search
could also be combined or substituted with custom shRNA libraries speciﬁcally
targeting these cofactors [127, 128].
Another interesting direction is to use an imaging-based approach to screen for
compoundsthateitherupregulateordownregulatetetramerization. Incancermod-
els with wild-type p53 the aim of the screen would be to identify drugs that boost
tetramerization, in the hope of enhancing p53 activity. On the other hand, com-
pounds that inhibit tetramerization would also be extremely useful, for instance
79in the case of cells heterozygous for p53. Here the product of a DNA-binding de-
fective allele is thought to oligomerize with wild-type p53, interfering with the
latter’s activity, in the so-called dominant negative effect. The BiFC experimental
system can be readily modiﬁed to combine expression of a wild-type copy of p53
together with a mutant counterpart; the complementation assay would then report
for hetero-oligomerization of p53 mutant and wild-type. With this setup, a chem-
ical screen could then be applied to identify compounds that speciﬁcally disrupt
the mutant to wild-type interaction, rescuing the function the wild-type.
In conclusion, the work in this thesis shows that the ability to reliably measure
p53 tetramerization has been instrumental to demonstrating directly the relation-
ship between tetramerization and transcriptonal activity of p53. Moreover, p53 is
only one example of how homo-oligomerization is used to control function. The
methods developed and discussed in this work can be applied to many other pro-
teins in the cell. The methods’ complementarity allows for spatial resolution of
cellular compartments and both short and long timescales, making them widely
applicable to ask fundamental and novel questions about the dynamics of protein
homo-oligomerization in live single cells.
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